Books
Silverman, R.B. Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology, Vols. I and II; CRC Press: Boca Raton, FL; 1988.
2a. Silverman, R.B. The Organic Chemistry of Drug Design and Drug Action; Academic Press: San Diego; 1992.
2b. Silverman, R. B. Medizinische Chemie für Organiker, Biochemiker und Pharmazeutische Chemiker, VCH: Weinheim; 1995 (German Translation by Joachim K. Seydel of The Organic Chemistry of Drug Design and Drug Action).
3. Silverman, R. B. The Organic Chemistry of Enzyme-Catalyzed Reactions, Academic Press: San Diego; 2000; revised, 2002.
4. Silverman, R.B. The Organic Chemistry of Drug Design and Drug Action; 2nd Edition; Elsevier/Academic Press: San Diego; 2004.
5. Silverman, R.B.; Holladay, M. W. The Organic Chemistry of Drug Design and Drug Action; 3rd Edition; Elsevier/Academic Press: San Diego; 2014.
Articles
1. Silverman, R.B.; Olofson, R.A. Chem. Commun., 1968, 1313. “The Oxidation of Tungsten Carbonyl in Carbon Tetrachloride.”
2. Klayman, D.L.; Kenny, D.; Silverman, R.B.; Tomaszewski, J.E.; Shine, R.J. J. Org. Chem., 1971, 36, 3681-3686. “The Action of Hydrogen Sulfide on Aminoalkanethiosulfuric Acids (Bunte Salts) to Give Di-, Tri-, and Tetrasulfides.”
3. Silverman, R.B.; Dolphin, D.; Babior, B.M. J. Am. Chem. Soc., 1972, 94, 4028-4030. “A Model for the Mechanism of Action of Coenzyme B12 Dependent Enzymes. Evidence for σÆ π Rearrangements in Cobaloximes.”
4. Silverman, R.B.; Dolphin, D. J. Am. Chem. Soc., 1973, 95, 1686-1688. “A Direct Method for Cobalt-Carbon Bond Formation in Cobalt (III)-Containing Cobalamins and Cobaloximes. Further Support for Cobalt(III) π Complexes in Coenzyme B12 Dependent Rearrangements.”
5. Silverman, R.B. in Klayman, D.L.; Gunther, W.H.H. Organic Selenium Compounds: Their Chemistry and Biology, Chapter VII, Wiley-Interscience, New York, 1973. “Selenium Analogs of Aldehydes and Ketones.”
6. Silverman, R.B. in Klayman, D.L.; Gunther, W.H.H. Organic Selenium Compounds: Their Chemistry and Biology, Chapter XI, Wiley-Interscience, New York, 1973. “Miscellaneous Selenium-Containing Heterocycles.”
7. Silverman, R.B.; Dolphin, D. J. Am. Chem. Soc., 1974, 96, 7094-7096. “Reactions of Vinyl Ethers with Cobaloximes and Cobalamins.”
8. Silverman, R.B.; Dolphin, D.; Carty, T.J.; Krodel, E.K.; Abeles, R.H. J. Am. Chem. Soc., 1974, 96, 7096-7097. “Formylcobalamin.”
9. Silverman, R.B.; Dolphin, D. J. Am. Chem. Soc., 1975, 97, 2924-2925. “On the Mechanisms of Hydrolysis of β-Acetal Cobalamins.”
10. Silverman, R.B.; Dolphin, D. J. Organometal. Chem., 1975, 101, C14-C16. “Hydrolysis of β-Acetal Cobaloximes.”
11. Silverman, R.B.; Dolphin, D. J. Am. Chem. Soc., 1976, 98, 4626-4633. “Model Studies for Coenzyme B12-Dependent Enzyme-Catalyzed Rearrangements: Evidence for Co(III)-p Complexes.”
12. Silverman, R.B.; Dolphin, D. J. Am. Chem. Soc., 1976, 98, 4633-4639. “Model Studies for Coenzyme B12-Dependent Enzyme-Catalyzed Rearrangements: Kinetics and Mechanism of Decomposition of Formylmethyl-cobalamin and Its Acetals.”
13. Silverman, R.B.; Dolphin, D. Can. J. Chem., 1976, 54, 1425-1427. “Alkylation of the Dimethylglyoximato Ligands in Reduced Cobaloxime.”
14. Silverman, R.B.; Abeles, R.H. Biochemistry, 1976, 15, 4718-4723. “Inactivation of Pyridoxal Phosphate-Dependent Enzymes by Mono- and Polyhaloalanines.”
15. Silverman, R.B.; Abeles, R.H. Biochemistry, 1977, 16, 5515-5520. “Mechanism of Inactivation of γ-Cystathionase by β,β,β-Trifluoroalanine.”
16. Silverman, R.B.; Kapili, L.V. J. Chromatography, 1978, 161, 415-416. “Paper Chromatographic and Electrophoretic Separations of Orotic Acid, 5-Fluoroorotic Acid, 5-Fluorouracil, and 5-Fluorouridine 5′-Monophosphate.”
17. Silverman, R.B. J. Heterocycl. Chem., 1978, 15, 1519-1520. “Reaction of Diethyl Acetonedicarboxylate with Nitrosyl Chloride.”
18. Silverman, R.B.; Kapili, L.V. J. Label. Compounds Radiopharm., 1979, 16, 361-364. “Synthesis of [Carboxyl-14C]5-Fluoroorotic Acid.”
19. Silverman, R.B.; Hoffman, S.J. in Kalman, T.I. (Edit.) Drug Action and Design: Mechanism-Based Enzyme Inhibitors, Elsevier-North Holland, N.Y., 1979, pp 175-186, “Mechanism of Inactivation of Mitochondrial Monoamine Oxidase by Cyclopropylamines.”
20. Silverman, R.B.; Hoffman, S.J. in Singer, T.P.; Von Korff, R.W.; Murphy, D.L. (Edit.) Monoamine Oxidase: Structure, Function, and Altered Functions, Academic Press, N.Y., 1979, pp 71-79, “Mechanism of Inactivation of Monoamine Oxidase by N-Cyclopropyl-N-Arylalkyl Amines.”
21. Silverman, R.B.; Radak, R.E.; Hacker, N.P. J. Org. Chem., 1979, 44, 4970-4971. “A Mild Method of Hydrolysis of 2,4-Dialkoxy-6-Substituted Pyrimidines to 6-Substituted Uracils.”
22. Dolphin, D.; Banks, A.R.; Cullen, W.R.; Cutler, A.R.; Silverman, R.B. in Zagalak, B.; Friedrich, W. (Edit.) Proceedings of the Third European Symposium on Vitamin B12 and Intrinsic Factor, Walter deGruyter, Inc., Berlin and N.Y., 1979. “The Mechanism of Action of Coenzyme B12.”
23. Bulkowski, J.; Cutler, A.; Dolphin, D.; Silverman, R.B. Inorganic Syntheses, 1980, 20, 127-134. “Bis[2,3-butanedionedioximato (1-)]cobalt Complexes.”
24. Dolphin, D.; Halko, D.J.; Silverman, R.B. Inorganic Syntheses, 1980, 20, 134-142. “Cobalamins and Cobinamides.”
25. Silverman, R.B.; Levy, M.A. J. Org. Chem., 1980, 45, 815-818. “Syntheses of (S)-5-Substituted-4-Aminopentanoic Acids: A New Class of γ-Aminobutyric Acid Transaminase Inactivators.”
26. Silverman, R.B.; Hoffman, S.J. J. Am. Chem. Soc., 1980, 102, 884-886. “Mechanism of Inactivation of Mitochondrial Monoamine Oxidase by N-Cyclopropyl-N-Arylalkyl Amines.”
27. Silverman, R.B.; Dolphin, D. J. Chromatography, 1980, 194, 273-274. “Thin-Layer Chromatography of Acid-Labile Cobalamins.”
28. Silverman, R.B. J. Am. Chem. Soc., 1980, 102, 5421-5423. “A Model for a “Molecular Mechanism of Anticoagulant Activity of 3-Substituted-4-Hydroxycoumarins.”>
29. Silverman, R.B.; Levy, M.A. Biochem. Biophys. Res. Comm., 1980, 95, 250-255. “Irreversible Inactivation of Pig Brain γ-Aminobutyric Acid-α-Ketoglutarate Transaminase by 4-Amino-5-halopentanoic Acids.”
30. Silverman, R.B.; Hoffman, S.J.; Catus, W.B., III J. Am. Chem. Soc., 1980, 102, 7126-7128. “A Mechanism for Mitochondrial Monoamine Oxidase-Catalyzed Amine Oxidation.”
31. R.B. Silverman, J. Am. Chem. Soc., 1981, 103, 3910-3915. “Model Studies for a Molecular Mechanism of Action of Oral Anticoagulants.”
32. Silverman, R.B.; Hoffman, S.J. J. Label. Compounds Radiopharm., 1981, 18, 781-790. “Syntheses of N-[1-2H]-, N-[1-3H]cyclopropylbenzylamine and [phenyl-14C]N-cyclopropylbenzylamine.”
33. Silverman, R.B.; Levy, M.A. Biochemistry, 1981, 20, 1197-1203. “Mechanism of Inactivation of γ-Aminobutyric Acid-α-Ketoglutaric Acid Aminotransferase by 4-Amino-5-halopentanoic Acids.”
34. Silverman, R.B.; Levy, M.A. J. Biol. Chem., 1981, 256, 11565-11568. “Substituted 4-Aminobutanoic Acids: Substrates for γ-Aminobutyric Acid-α-Ketoglutaric Acid Aminotransferase.”
35. Silverman, R.B. J. Am. Chem. Soc., 1981, 103, 5939-5941, “Chemical Model Studies for the Mechanism of Vitamin K Epoxide Reductase.”
36. Silverman, R.B. J. Org. Chem., 1981, 46, 4789-4791, “Mechanism of Isomerization of a β-Ketosulfide.”
37. Silverman, R.B.; Hoffman, S.J. Biochem. Biophys. Res. Commun. 1981, 101, 1396-1401. “N-(1-Methyl)Cyclopropylbenzylamine: A Novel Inactivator of Mitochondrial Monoamine Oxidase.”
38. Silverman, R.B.; Levy, M.A.; Muztar, A.J.; Hirsch, J.D. Biochem. Biophys. Res. Commun., 1981, 102, 520-523. “In Vivo Inactivation of γ-Aminobutyric Acid-α-Ketoglutarate Transaminase by 4-Amino-5-fluoropentanoic Acid.”
39. Silverman, R.B.; Holladay, M.W. J. Am. Chem. Soc., 1981, 103, 7357-7358. “Stereospecific Total Syntheses of the Antitumor Agent [αS,5S]-α-Amino-3-chloro-4,5-dihydro-5-isoxazoleacetic Acid and Its C-5 Epimer.”
40. Silverman, R.B.; Hoffman, S.J.; Catus, W.B., III in Flavins and Flavoproteins, (V. Massey and C.H. Williams, Jr., eds.) Elsevier-North Holland, N.Y., 1982, pp. 213-216, “A Mechanism for Mitochondrial Monoamine Oxidase-Catalyzed Amine Oxidation.”
41. Silverman, R.B.; Groziak, M.P. J. Am. Chem. Soc., 1982, 104, 6434-6439. “Model Chemistry for a Covalent Mechanism of Action of Orotidine 5′-Phosphate Decarboxylase.”
42. Silverman, R.B.; Muztar, A.J.; Levy, M.A.; Hirsch, J.D. Life Sci., 1983, 32, 2717-2723. “In Vitro and In Vivo Effects on Brain GABA Metabolism of (S)-4-Amino-5-fluoropentanoic Acid, A Mechanism-based Inactivator of γ-Aminobutyric Acid Transaminase.”
43. Silverman, R.B. J. Biol. Chem., 1983, 258, 14766-14769. “Mechanism of Inactivation of Monoamine Oxidase by trans-2-Phenylcyclopropylamine and the Structure of the Enzyme-Inactivator Adduct.”
44. Silverman, R.B.; Hoffman, S.J. Med. Res. Rev., 1984, 4, 415-447. “The Organic Chemistry of Mechanism-Based Enzyme Inhibition: A Chemical Approach to Drug Design.”
45. Silverman, R.B.; Yamasaki, R.B. Biochemistry, 1984, 23, 1322-1332. “Mechanism-based Inactivation of Mitochondrial Monoamine Oxidase by N-(1-Methylcyclopropyl)benzylamine.”
46. Silverman, R.B. Biochemistry, 1984, 23, 5206-5213. “Effect of a-Methylation on the Inactivation of Monoamine Oxidase by N-Cyclopropylbenzylamine.”
47. Silverman, R.B.; Tan, J.L. J. Org. Chem., 1984, 49, 4560-4562, “Mechanism for the Reaction of trans-2-Phenylcyclopropylamine with Nitrous Acid.”
48. Silverman, R.B.; Zieske, P.A. Biochemistry, 1985, 24, 2128-2138, “Mechanism of Inactivation of Monoamine Oxidase by 1-Phenylcyclopropylamine.”
49. Mukharji, I.; Silverman, R.B. Proc. Natl. Acad. Sci. (USA), 1985, 82, 2713-2717, “Purification of a Vitamin K Epoxide Reductase Which Catalyzes the Conversion of Vitamin K 2,3-epoxide to 3-Hydroxy-2-methyl-3-phytyl-2,3-dihydronaphthoquinone.”
50. Mathew, J.; Invergo, B.J.; Silverman, R.B. Syn. Commun., 1985, 15, 377-383. “An Efficient Synthesis of 3-Amino-4-fluorobutanoic Acid, an Inactivator of GABA Transaminase.”
51. Silverman, R.B.; Zieske, P.A. J. Med. Chem., 1985, 28, 1953-1957. “1-Benzylcyclopropylamine and (1-Phenylcyclopropyl)methylamine, an Inactivator and a Substrate of Monoamine Oxidase.”
52. Vazquez, M.L.; Silverman, R.B. Biochemistry, 1985, 24, 6538-6543, “Revised Mechanism for Inactivation of Mitochondrial Monoamine Oxidase by N-Cyclopropylbenzylamine.”
53. Yamasaki, R.B.; Silverman, R.B. Biochemistry, 1985, 24, 6543-6550, “Mechanism for Reactivation of N-Cyclopropylbenzylamine-Inactivated Monoamine Oxidase by Amines.”
54. Silverman, R.B.; Hiebert, C.K.; Vazquez, M.L. J. Biol. Chem., 1985, 260, 14648-14652, “Inactivation of Monoamine Oxidase by Allylamine Does Not Result in Flavin Attachment.”
55. Silverman, R.B.; Durkee, S.C.; Invergo, B.J. J. Med. Chem., 1986, 29, 764-770. “4-Amino-2-(substituted methyl)-2-butenoic Acids: Substrates and Potent Inhibitors of γ-Aminobutyric Acid Aminotransferase.”
56. Silverman, R.B. in Protein Tailoring for Food and Medical Uses (R.E. Feeney and J.R. Whitaker, Eds.), Marcel Dekker, N.Y., 1986, Chapter 8, pp 215-241, “Mechanism-Based Enzyme Inactivators for Medical Uses.”
57. Silverman, R.B.; Zieske, P.A. Biochemistry, 1986, 25, 341-346, “1-Phenylcyclobutylamine, the First in a New Class of Monoamine Oxidase Inactivators. Further Evidence for a Radical Intermediate.”
58. Silverman, R.B.; Zieske, P.A. Biochem. Biophys. Res. Commun., 1986, 135, 154-159, “Identification of the Amino Acid Bound to the Labile Adduct Formed During Inactivation of Monoamine Oxidase by 1-Phenylcyclopropylamine.”
59. Silverman, R.B.; Invergo, B.J.; Mathew, J. J. Med. Chem., 1986, 29, 1840-1846, “Inactivation of γ-Aminobutyric Acid Aminotransferase by (S,E)-4-Amino-5-fluoropent-2-enoic Acid and Effect on the Enzyme of (E)-3-(1-Aminocyclopropyl)-2-propenoic Acid.”
60. Silverman, R.B.; Invergo, B.J. Biochemistry, 1986, 25, 6817-6820, “Mechanism of Inactivation of γ-Aminobutyrate Aminotransferase by 4-Amino-5-fluoropentanoic Acid. First Example of an Enamine Mechanism for a γ-Amino Acid with a Partition Ratio of O.”
61. Silverman, R.B.; Invergo, B.J.; Levy, M.A.; Andrew, C.R. J. Biol. Chem., 1987, 262, 3192-3195, “Substrate Stereospecificity and Active Site Topography of γ-Aminobutyric Acid Aminotransferase for β-Aryl-γ-aminobutyric Acid Analogues.”
62. Silverman, R.B.; Banik, G.M. J. Am. Chem. Soc., 1987, 109, 2219-2220, “(Aminoalkyl)trimethylsilanes. A New Class of Monoamine Oxidase Inactivators.”
63. Silverman, R.B.; Vadnere, M.K. Bioorg. Chem., 1987, 15, 328-332, “Aminoalkyltrimethylgermanes: The First Organogermanium Mechanism-Based Enzyme Inactivators. A New Class of Monoamine Oxidase Inactivators.”
64. Silverman, R.B.; Mukharji, I.; Nandi, D.L. in Current Advances in Vitamin K Research (J. W. Suttie, Ed.), Elsevier/North-Holland, New York, 1988, 65-74, “Solubilization, Partial Purification, Mechanism, and Inactivation of Vitamin K Epoxide Reductase.”
65. Silverman, R.B.; George, C. Biochem. Biophys. Res. Commun. 1988, 150, 942-946, “Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase by (S,E)-4-Amino-5-fluoropent-2-enoic Acid.”
66. Silverman, R.B. J. Enz. Inhib. 1988, 2, 73-90, “The Potential Use of Mechanism-Based Enzyme Inactivators in Medicine.”
67. Silverman, R.B. in Topics in Medicinal Chemistry (4th SCI-RSC Medicinal Chemistry Symposium; P. R. Leeming, Ed., Royal Society of Chemistry, London, 1988, pp. 73-100, “Enzyme Inhibition: Approaches to Drug Design.”
68. Silverman, R.B.; George, C. Biochemistry, 1988, 27, 3285-3289, “Inactivation of γ-Aminobutyric Acid Aminotransferase by (Z)-4-Amino-2-fluoro-2-butenoic Acid.”
69. Hiebert, C.K.; Silverman, R.B. J. Med. Chem., 1988, 31, 1566-1570, “1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Analogues. Inactivation of Monoamine Oxidase by Conformationally-Rigid Analogues of N,N-Dimethylcinnamylamine.”
70. Silverman, R.B.; Hiebert, C.K. Biochemistry, 1988, 27, 8448-8453, “Inactivation of Monoamine Oxidase A by the Monoamine Oxidase B Inactivators 1-Phenylcyclopropylamine, 1-Benzylcyclopropylamine, and N-Cyclopropyl-β-methylbenzylamine.”
71. Silverman, R.B.; Nandi, D.L. Biochem. Biophys. Res. Commun. 1988, 155, 1248-1254, “Reduced Thioredoxin: A Possible Physiological Cofactor for Vitamin K Epoxide Reductase. Further Support for an Active Site Disulfide.”
72. Yelekci, K.; Lu, X.; Silverman, R.B. J. Am. Chem. Soc. 1989, 111, 1138-1140, “Electron Spin Resonance Studies of Monoamine Oxidase B. First Direct Evidence for a Substrate Radical Intermediate.”
73. Silverman, R.B.; Oliver, J. S. J. Med. Chem., 1989, 32, 2138-2141, “2-Fluoromethyl-3-phytyl-1,4-naphthoquinone and its 2,3-Epoxide. Inhibition of Vitamin K Epoxide Reductase.”
74. Andruszkiewicz, R.; Silverman, R.B. Synthesis, 1989, 953-955, “A Convenient Synthesis of 3-Alkyl-4-aminobutanoic Acids.”
75. Gates, K.S.; Silverman, R.B. J. Am. Chem. Soc., 1989, 111, 8891-8895, “Model Studies for the Mechanism of Inactivation of Monoamine Oxidase by 5-Aminomethyl-3-aryl-2-oxazolidinones.”
76. Nanavati, S.M.; Silverman, R.B. J. Med. Chem., 1989, 32, 2413-2421, “Design of Potential Anticonvulsant Agents: Mechanistic Classification of γ-Aminobutyric Acid Aminotransferase Inactivators.”
77. Hiebert, C.K.; Sayre, L.M.; Silverman, R.B. J. Biol. Chem., 1989, 264, 21516-21521, “Inactivation of Monoamine Oxidase by 3,3-Dimethyl Analogues of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-Methyl-4-phenyl-2,3-dihydropyridinium Ion (MPDP+). Dramatic effect of β-Mercaptoethanol on Substrate Turnover and Enzyme Inactivation.”
78. Silverman, R.B.; Nanavati, S.M. J. Med. Chem., 1990, 33, 931-936, “Selective Inhibition of γ-Aminobutyric Acid Aminotransferase by (3R,4R),(3S,4S) and (3R,4S),(3S,4R)-4-Amino-5-fluoro-3-phenylpentanoic Acids.”
79. Andruszkiewicz, R.; Barrett, A.G.M.; Silverman, R.B. Syn. Commun., 1990, 20, 159-166, “Chemoenzymatic Synthesis of (R)- and (S)-4-Amino-3-methylbutanoic Acids.”
80. Ryall, R.P.; Silverman, R.B. Syn. Commun., 1990, 20, 431-438, “Synthesis of 2-Substituted-3-phytyl-1,4-naphthoquinone Epoxides.”
81. Banik, G.M.; Silverman, R.B. J. Am. Chem. Soc., 1990, 112, 4499-4507, “Mechanism of Inactivation of Monoamine Oxidase B by (Aminomethyl)trimethylsilane.”
82. Silverman, R.B.; Nandi, D.L. J. Enz. Inhib. 1990, 3, 289-294, “Effect of N-Ethylmaleimide on Beef and Rat Liver Vitamin K1 Epoxide Reductase.”
83. Ryall, R.P.; Nandi, D.L.; Silverman, R.B. J. Med. Chem., 1990, 33, 1790-1797, “Substituted Vitamin K Epoxide Analogues. New Competitive Inhibitors and Substrates of Vitamin K1 Epoxide Reductase.”
84. Gates, K.S.; Silverman, R.B. J. Am. Chem. Soc., 1990, 112, 9364-9372, “5-(Aminomethyl)-3-aryl-2-oxazolidinones. A Novel Class of Mechanism-Based Inactivators of Monoamine Oxidase B.”
85. Andruszkiewicz, R.; Silverman, R.B. J. Biol. Chem., 1990, 265, 22288-22291, “4-Amino-3-alkylbutanoic Acids as Substrates for γ-Aminobutyric Acid Aminotransferase.”
86. Silverman, R.B. Biochem. Soc. Trans., 1991, 19, 201-206, “The Use of Mechanism-Based Inactivators to Probe the Mechanism of Monoamine Oxidase.”
87. Silverman, R.B.; Andruszkiewicz, R.; Nanavati, S.M.; Taylor, C.P.; Vartanian, M.G. J. Med. Chem., 1991, 34, 2295-2298. “3-Alkyl-4-aminobutyric Acids: The First Class of Anticonvulsant Agents That Activates L-Glutamic Acid Decarboxylase.”
88. Burke, J.R.; Silverman, R.B. J. Enz. Inhib., 1991, 5, 199-205. “4-(Oxoalkyl)-substituted GABA Analogues as Inactivators and Substrates of GABA Aminotransferase.”
89. Burke, J.R.; Silverman, R.B. J. Am. Chem. Soc., 1991, 113, 9329-9340. “Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase by 4-Amino-5-hexynoic Acid (γ-Ethynyl GABA).”
90. Nanavati, S.M.; Silverman, R.B. J. Am. Chem. Soc., 1991, 113, 9341-9349. “Mechanisms of Inactivation of γ-Aminobutyric Acid Aminotransferase by the Antiepilepsy Drug γ-Vinyl GABA (Vigabatrin).”
91. Taylor, C.P.; Vartanian, M.G.; Andruszkiewicz, R.; Silverman, R.B. Epilepsy Res. 1992, 11, 103-110. “3-Alkyl GABA and 3-Alkylglutamate Analogues: Two New Classes of Anticonvulsant Agents.”
92. Ding, Z.; Silverman, R.B. J. Med. Chem. 1992, 35, 885-889. “5-(Aminomethyl)-3-aryldihydrofuran-2(3H)-ones, a New Class of Monoamine Oxidase-B Inactivators.”
93. Silverman, R.B. In Advances in Electron Transfer Chemistry, Vol. 2; Mariano, P.S., Ed.; JAI Press: Greenwich, CT, 1992; pp. 177-213. “Electron Transfer Chemistry of Monoamine Oxidase.”
94. Hopkins, M.H.; Silverman, R.B. J. Enz. Inhib. 1992, 6, 125-129. “β-Lactams: A New Class of Conformationally-Rigid Inhibitors of γ-Aminobutyric Acid Aminotransferase.”
95. Hopkins, M.H.; Silverman, R.B. BioMed. Chem. Lett. 1992, 2, 1371-1374. “α-Amino Acid Analogues as Mechanism-Based Inactivators of γ-Aminobutyric Acid Aminotransferase.”
96. Hopkins, M.H.; Bichler, K.A.; Su, T.; Chamberlain, C.L.; Silverman, R.B. J. Enz. Inhib. 1992, 6, 195-199. “Inactivation of γ-Aminobutyric Acid Aminotransferase by Various Amine Buffers.”
97. Ding, C.Z.; Silverman, R.B. J. Enz. Inhib. 1992, 6, 223-231. “4-(Aminomethyl)-1-Aryl-2-pyrrolidinones, a New Class of Monoamine Oxidase B Inactivators.”
98. Zelechonok, Y.; Silverman, R.B. J. Org. Chem. 1992, 57, 5785-5787. “Mechanism for the Reaction of Tributyltin Radicals with Aldehydes.”
99. Zelechonok, Y.; Silverman, R.B. J. Org. Chem. 1992, 57, 5787-5790. “Silver (I)/Peroxydisulfate-Induced Oxidative Decarboxylation of Amino Acids. A Chemical Model for a Possible Intermediate in the Monoamine Oxidase-Catalyzed Oxidation of Amines.”
100. Silverman, R.B.; Zelechonok, Y. J. Org. Chem. 1992, 57, 6373-6374. “Evidence for a Hydrogen Atom Transfer Mechanism or a Proton/Fast Electron Transfer Mechanism for Monoamine Oxidase.”
101. Silverman, R.B.; Lu, X.L.; Banik, G.M. J. Org. Chem. 1992, 57, 6617-6622. “Formylsilanes. Chemoenzymatic and Chemical Syntheses of the 2,4-Dinitrophenylhydrazones of These Apparently Air- and Water-Stable Compounds.”
102. Silverman, R.B.; Ding, C.Z.; Gates, K.S. Perspectives in Medicinal Chemistry ; Testa, B.; Kyburz, E.; Fuhrer, W.; Giger, R., Eds.; Verlag Helvetica Chimica Acta: Basel; 1993, 73-86. “Design and Mechanism of Monoamine Oxidase Inactivators from a Chemical Perspective.”
103. Silverman, R.B.; Nishimura, K.; Lu, X. J. Am. Chem. Soc. 1993, 115, 4949-4954. “Mechanism of Inactivation of Monoamine Oxidase-B by the Anticonvulsant Agent Milacemide (2-(n-Pentylamino)acetamide).”
104. Silverman, R.B.; Ding, C.Z.; Borrillo, J.L.; Chang, J.T. J. Am. Chem. Soc. 1993, 115, 2982-2983. ” Mechanism-Based Enzyme Inactivation via a Diactivated Cyclopropane Intermediate.”
105. Nishimura, K.; Lu, X.; Silverman, R.B. J. Med. Chem. 1993, 36, 446-448. “Inactivation of Monoamine Oxidase B by Analogues of the Anticonvulsant Agent Milacemide (2-n-Pentylaminoacetamide).”
106. Silverman, R.B.; Cesarone, J.M.; Lu, X. J. Am. Chem. Soc. 1993, 115, 4955-4961. “Stereoselective Ring Opening of 1-Phenylcyclopropylamine Catalyzed by Monoamine Oxidase-B.”
107. Silverman, R. B.; Ding, C.Z. J. Am. Chem. Soc. 1993, 115, 4571-4576. “A Chemical Model for the Mechanism of Inactivation of Monoamine Oxidase by Heterocyclic Compounds. Electronic Effects on Acetal Hydrolysis”
108. Lu, X.; Silverman, R.B. J. Enz. Inhib. 1993, 7, 43-45. “The Antiulcer Drug Ranitidine Hydrochloride and its Synthetic Intermediates are Inactivators of Monoamine Oxidase-B.”
109. Ding, C.Z.; Silverman, R.B. Syn. Commun. 1993, 23, 1467-1471. “Synthesis of N-Carbobenzoxy-N,N-acetals.”
110. Ding, C.Z.; Lu, X.; Nishimura, K.; Silverman, R.B. J. Med. Chem., 1993, 36, 1711-1715. “Transformation of Monoamine Oxidase-B Primary Amine Substrates into Time-Dependent Inhibitors. Tertiary Amine Homologues of Primary Amine Substrates.”
111. Silverman, R.B.; Tran, N.; Sinha, R.K.; Neuhaus, F.C. Biochem. Biophys. Res. Commun. 1993, 195, 1077-1080. “The Oxazolidinone Antibacterial Agent DuP 105 Does Not Act on Cell Wall Biosynthesis or on a β-Lactamase.”
112. Ding, C. Z.; Silverman, R. B. BioMed. Chem. Lett. 1993, 3, 2077-2078. “Selective Inactivation of Monoamine Oxidase B by Aminoethyl 3-Chlorobenzyl Ether.”
113. Silverman, R. B.; Zhou, J. P.; Eaton, P. E. J. Am. Chem. Soc. 1993, 115, 8841-8842. “Inactivation of Monoamine Oxidase by (Aminomethyl)cubane. First Evidence for an α-Amino Radical During Enzyme Catalysis.”
114. Ding, C. Z.; Silverman, R. B. J. Med. Chem. 1993, 36, 3606-3610. “Transformation of Heterocyclic Reversible Monoamine Oxidase-B Inactivators into Irreversible Inactivators by N-Methylation.”
115. Annan, N.; Silverman, R. B. J. Med. Chem., 1993, 36, 3968-3970. “New Analogues of N-(2-Aminoethyl)-4-chlorobenzamide (Ro 16-6491). Some of the Most Potent Monoamine Oxidase-B Inactivators.”
116. Silverman, R. B.; Lu, X. J. Am. Chem. Soc. 1994, 116, 4129-4130. “Evidence Against a Nucleophilic Mechanism for Monoamine Oxidase-Catalyzed Amine Oxidation.”
117. Woo, J. C. G.; Silverman, R. B. Biochem. Biophys. Res. Commun. 1994, 202, 1574-1578. “Observation of Two Different Chromophores in the Resting State of Monoamine Oxidase B by Fluorescence Spectroscopy.”
118. Silverman, R. B.; Lu, X.; Zhou, J. J. P.; Swihart, A. J. Am. Chem. Soc. 1994, 116, 11590-11591. “Monoamine Oxidase B-Catalyzed Oxidation of Cinnamylamine-2,3-oxide. Further Evidence against a Nucleophilic Mechanism.”
119. Silverman, R. B.; Olson, G. T. Bioorg. Med. Chem., 1995, 3, 11-18. “Inactivation of γ-Aminobutyric Acid Aminotransferase by L-3-Chloroalanine Hydroxamate.”
120. Silverman, R. B. Methods Enzymol. 1995, 249, 240-283. “Mechanism-Based Enzyme Inactivators.”
121. Silverman, R. B.; Hawe, W. P. J. Enz. Inhib., 1995, 9, 203-215. “SAR Studies of Fluorine-Substituted Benzylamines and Substituted 2-Phenylethylamines as Substrates and Inactivators of Monoamine Oxidase B.”
122. Silverman, R. B. Prog. Brain Res. 1995, 106, 23-31. “Radical Thoughts about the Life of MAO.”
123. Woo, J. C. G.; Silverman, R. B. J. Am. Chem. Soc., 1995, 117, 1663-1664. “Monoamine Oxidase B Catalysis in Low Aqueous Medium. Direct Evidence for an Imine Product.”
124. Zhou, J. J. P.; Zhong, B.; Silverman, R. B. J. Org. Chem. 1995, 60, 2261-2262. “Improved Procedure for the Synthesis of Substituted β-Hydroxynitriles.”
125. Lightcap, E. S.; Hopkins, M. H.; Olson, G. T.; Silverman, R. B. Bioorg. Med. Chem. 1995, 3, 579-585. “Time-Dependent Inhibition of γ-Aminobutyric Acid Aminotransferase by 3-Hydroxybenzylhydrazine.”
126. Silverman, R. B.; Olson, G. T. J. Org. Chem. 1995, 60, 6232-6234. “Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase by 3-Hydrazinopropionic Acid.”
127. Woo, J. C. G.; Wang, X.; Silverman, R. B. J. Org. Chem. 1995, 60, 6235-6236. “Monoamine Oxidase-Catalyzed Amine Oxidation in Organic Solvents.”
128. Silverman, R. B. Acc. Chem. Res. 1995, 28, 335-342. “Radical Ideas About Monoamine Oxidase.”
129. Silverman, R. B.; Zhou, J. J. P.; Ding, C. Z.; Lu, X. J. Am. Chem. Soc. 1995, 117, 12895- 12896. “Monoamine Oxidase-Catalyzed Oxidative Decarboxylation of cis– and trans-5- Aminomethyl-3-(4-methoxyphenyl)dihydrofuran-2(3H)-one. Evidence for the Intermediacy of an α-Radical.”
130. Lightcap, E. S.; Silverman, R. B. J. Med. Chem. 1996, 39, 686-694. “Slow-binding Inhibition of γ-Aminobutyric Acid Aminotransferase by Hydrazine Analogues.”
131. Zhou, J. J. P.; Zhong, B.; Silverman, R. B. Anal. Biochem. 1996, 234, 9-12. “Direct Continuous Fluorometric Assay for Monoamine Oxidase B.”
132. Silverman, R. B.; Bichler, K. A.; Leon, A. J. J. Am. Chem. Soc. 1996, 118, 1241-1252. “Mechanisms of Inactivation of γ-Aminobutyric Acid Aminotransferase by 4-Amino-5-fluoro-5-hexenoic Acid.”
133. Silverman, R. B.; Bichler, K. A.; Leon, A. J. J. Am. Chem. Soc. 1996, 118, 1253-1261. “Unusual Mechanistic Difference in the Inactivation of γ-Aminobutyric Acid Aminotransferase by (E)- and (Z)-4-Amino-6-fluoro-5-hexenoic Acids.”
134. Silverman, R. B.; Olson, G. T. Bioorg. Med. Chem. Lett. 1996, 6, 143-146. “3-Substituted Alanines Inactivate γ-Aminobutyric Acid Aminotransferase by the Same Mechanism as do 4-Amino-5-halopentanoic Acid Analogues.”
135. Silverman, R. B.; Roscher, C. L.C. Bioorg. Med. Chem. 1996, 4, 1521-1535. “Mechanism-Based Inactivation of γ-Aminobutyric Acid Aminotransferase by 3-Amino-4-fluorobutanoic Acid.”
136. Leon, A. J.; Silverman, R. B. Bioorg. Med. Chem. Lett. 1996, 6, 1319-1322. “Inactivation of γ-Aminobutyric Acid Aminotransferase by (Z)-4-Amino-6-fluoro-5-hexenoic Acid: Identification of an Active Site Residue.”
137. DeRose, V.J.; Woo, J.C.G.; Hawe, W.P.; Hoffman, B.M.; Silverman, R.B.; Yelekci, K. Biochemistry 1996, 35, 11085-11091. “Characterization of a Flavin Semiquinone in the Resting State of Monoamine Oxidase B by Electron Paramagnetic Resonance and Electron Nuclear Double Resonance Spectroscopy.”
138. Silverman, R. B. In Contemporary Enzyme Kinetics and Mechanism, 2nd edition; Purich, D. L., ed.; Academic Press: San Diego, 1996, pp. 291-334. “Mechanism-Based Enzyme Inactivators.”
139. Lu, X.; Yang, S.; Silverman, R.B. J. Org. Chem., 1996, 61, 8961-8966. “Monoamine Oxidase-Catalyzed Oxidative Rearrangement of trans, trans-1-(Aminomethyl)-2-methoxy-3-phenylcyclopropane.”
140a. Silverman, R. B.; Lu, X.; Blomquist, G.; Ding, C. Z.; Yang, S. Bioorg. Med. Chem. 1997,5, 297-304. “Inactivation of Monoamine Oxidase B by Benzyl 1-(Aminomethyl)cyclopropane-1-carboxylate.”
140b. Silverman, R. B.; Lu, X.; Blomquist, G.; Ding, C. Z.; Yang, S. Bioorg. Med. Chem. 1998,6, 365. Corrigendum to “Inactivation of Monoamine Oxidase B by Benzyl 1-(Aminomethyl)cyclopropane-1-carboxylate.”
141. Zhou, J. P.; Li, J.; Upadhyaya, S.; Eaton, P. E.; Silverman, R. B. J. Med. Chem. 1997, 40, 1165-1168. “4-Substituted Cubylcarbinyl Amines: A New Class of Mechanism-Based Monoamine Oxidase B Inactivators.”
142. Silverman, R. B. Il Farmaco, 1997, 52, 343-352. “Oxazolidinones, Dihydrofuranones, and Pyrrolidinones as Inactivators and Substrates of Monoamine Oxidase B: Approaches to the Design of Antiparkinsonian Agents.”
143. Fast, W.; Levsky, M. E.; Marletta, M. A.; Silverman, R. B., Bioorg. Med. Chem. 1997, 5, 1601-1608. “Nω-Propargyl-L-arginine and Nω-Hydroxy-Nω-propargyl-L-arginine are Inhibitors, but Not Inactivators, of Neuronal and Macrophage Nitric Oxide Synthases.”
144. Fast, W.; Huff, M. E.; Silverman, R. B. Bioorg. Med. Chem. Lett. 1997, 7, 1449-1454. “Time-Dependent Inhibition of Neuronal Nitric Oxide Synthase by N-Propargylguanidine.”
145. Zhong, B.; Silverman, R. B. J. Am. Chem. Soc. 1997, 119, 6690-6691. “Identification of the Active Site Cysteine in Bovine Liver Monoamine Oxidase B.”
146. Silverman, R. B.; Huang, H.; Marletta, M. A.; Martasek, P. J. Med. Chem. 1997, 40, 2813-2817. “Selective Inhibition of Neuronal Nitric Oxide Synthase by Nω-Nitroarginine- and Phenylalanine-Containing Dipeptides and Dipeptide Esters.”
147. Zhang, H. Q.; Dixon, R. P.; Marletta, M. A.; Nikolic, D.; Van Breemen, R.; Silverman, R. B., J. Am Chem. Soc. 1997, 119, 10888-10902. “Mechanism of Inactivation of Neuronal Nitric Oxide Synthase by Nω-Allyl-L-arginine.”
148. Zhang, H. Q.; Fast, W.; Marletta, M. A.; Martasek, P.; Silverman, R. B. J. Med. Chem. 1997, 40, 3869-3870. “Potent and Selective Inhibition of Neuronal Nitric Oxide Synthase by Nω-Propyl-L-arginine.”
149. Olson, G. T.; Fu, M.; Lau, S.; Rinehart, K. L.; Silverman, R. B., J. Am. Chem. Soc. 1998, 120, 2256-2267. “An Aromatization Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase for the Antibiotic L-Cycloserine.”
150. Yelekçi, K.; Silverman, R. B., J. Enzyme Inhib. 1998, 13, 31-39. “Effect of the Locus of the Oxygen Atom in Amino Ethers on the Inactivation of Monoamine Oxidase B.”
151. Lu, X.; Silverman, R. B. Bioorg. Med. Chem. 1998, 6, 1851-1856. “Inactivation of Monoamine Oxidase B by cis– and trans-5-Aminomethyl-3-(4-methoxyphenyl)dihydrofuran-2(3H)-ones.”
152. Lu, X.; Silverman, R. B. J. Am. Chem. Soc. 1998, 120, 10583-10587. “Monoamine Oxidase B-Catalyzed Reactions of cis– and trans-5-Aminomethyl-3-(4-methoxyphenyl)dihydrofuran-2(3H)-ones. Evidence for a Reversible Redox Reaction.”
153. Wang, X.; Silverman, R. B. J. Org. Chem. 1998, 63, 7357-7363. “2-(Iodoethenyl)benzyl Amines as Potential Probes for Radical Intermediates Formed During Monoamine Oxidase-Catalyzed Oxidations.”
154. Zhong, B.; Lu, X.; Silverman, R. B. Bioorg. Med. Chem. 1998, 6, 2405-2419. “Syntheses of Amino Nitrones. Potential Intramolecular Traps for Radical Intermediates in Monoamine Oxidase-Catalyzed Reactions.”
155. Fast, W.; Nikolic, D.; Van Breemen, R.; Silverman, R. B. J. Am. Chem. Soc. 1999, 121, 903-916. “Mechanism of Inactivation of Inducible Nitric Oxide Synthase by N5-(1-Iminoethyl)-L-ornithine (L-NIO).”
156. Lee, Y.; Marletta, M. A.; Martasek, P.; Roman, L. J.; Masters, B. S. S.; Silverman, R. B. Bioorg. Med. Chem., 1999, 7, 1097-1104. “Conformationally-restricted Arginine Analogues as Alternative Substrates and Inhibitors of Nitric Oxide Synthases.”
157. Qiu, J.; Stevenson, S. H.; O’Beirne, M. J.; Silverman, R. B. J. Med. Chem. 1999, 42, 329-332. “2,6-Difluorophenol as a Bioisostere of a Carboxylic Acid: Bioisosteric Analogues of γ-Aminobutyric Acid.”
158. Tierney, D. L.; Huang, H.; Martasek, P.; Masters, B. S. S.; Silverman, R. B.; Hoffman, B. M. Biochemistry 1999, 38, 3704-3710. “ENDOR Spectroscopic Evidence for the Position and Structure of NG-Hydroxy-L-arginine Bound to holo-Neuronal Nitric Oxide Synthase.”
159. Johnson, T. R.; Silverman, R. B. Bioorg. Med. Chem. 1999, 7, 1625-1636. “Syntheses of (Z)- and (E)-4-Amino-2-(trifluoromethyl)-2-butenoic Acid and Their Inactivation of γ-Aminobutyric Acid Aminotransferase.”
160. Fu, M.; Silverman, R. B. Bioorg. Med. Chem. 1999, 7, 1581-1590. “Isolation and Characterization of the Product of Inactivation of γ-Aminobutyric Acid Aminotransferase by Gabaculine.”
161. Huang, H.; Martasek, P.; Roman, L. J.; Masters, B. S. S.; Silverman, R. B. J. Med. Chem. 1999, 42, 3147-3153. “Nω-Nitroarginine-Containing Dipeptide Amides. Potent and Highly Selective Inhibitors of Neuronal Nitric Oxide Synthase.”
162. Lee, Y.; Martasek, P.; Roman, L. J.; Masters, B. S. S.; Silverman, R. B. Bioorg. Med. Chem. 1999, 7, 1941-1951. “Imidazole-Containing Amino Acids as Selective Inhibitors of Nitric Oxide Synthases.”
163. Lee, Y.; Silverman, R. B. Synthesis 1999, 1495-1499. “Solid-Phase Syntheses of Nω-Propylarginine-Containing Dipeptides, Dipeptide Esters, and Dipeptide Amides.”
164. Fu, M.; Nikolic, D.; Van Breemen, R.; Silverman, R. B. J. Am. Chem. Soc. 1999, 121, 7751-7759. “Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase by (S)-4-Amino-4,5-dihydro-2-thiophenecarboxylic Acid.”
165. Lee, Y.; Silverman, R. B. J. Am. Chem. Soc. 1999, 121, 8407-8408. “Efficient Solid-Phase Synthesis of Compounds Containing Phenylalanine and its Derivatives via Side-Chain Attachment to the Polymer Support.”
166. Qiu, J.; Pingsterhaus, J. M.; Silverman, R. B. J. Med. Chem. 1999, 42, 4725-4728. “Inhibition and Substrate Activity of Conformationally-Rigid Vigabatrin Analogues with γ-Aminobutyric Acid Aminotransferase.”
167. Woodroofe, C. C.; Mostashari, R.; Lu, X.; Ramsay, R. R.; Silverman, R. B. J. Enzyme Inhib. 1999, 15, 11-21. “Selective Inhibition of Monoamine Oxidase B by Aminoethyl Substituted Benzyl Ethers.”
168. Chebib, M.; Johnston, G. A. R.; Mattsson, J. P.; Rydström, K., Nilsson, K.; Qiu, J.; Stevenson, S. H.; Silverman, R. B. Bioorg. Med. Chem. Lett. 1999, 9, 3093-3098. “Aminomethyl-2,6-difluorophenols as a Novel Class of Increased Lipophilicity GABAC Receptor Antagonists.”
169. Tantillo, D.; Fukuto, J. M.; Hoffman, B. M.; Silverman, R. B.; Houk, K. N. J. Am. Chem. Soc. 2000, 122, 536-537. “Theoretical Studies on NG-Hydroxy-L-arginine and Derived Radicals: Implications for the Mechanism of Nitric Oxide Synthase.”
170. Koo, Y. K.; Nandi, D.; Silverman, R. B. Arch. Biochem. Biophys. 2000, 374, 248-254. “Multiple Active Enzyme Species of γ-Aminobutyric Acid Aminotransferase are not Isozymes, but are Proteolytic Fragments.”
171. Woodroofe, C. C.; Zhong, B.; Lu, X.; Silverman, R. B. J. Chem. Soc. Perkin Trans. 2 2000, 55-60. “Anomalous Schmidt Reaction Products of Phenylacetic Acid and Derivatives.”
172. Qiu, J.; Silverman, R. B. J. Med. Chem. 2000, 43, 706-720. “A New Class of Conformationally-Rigid Analogues of 4-Amino-5-halopentanoic Acids, Potent Inactivators of γ-Aminobutyric Acid Aminotransferase.”
173. Lee, Y.; Silverman, R. B. Organic Lett. 2000, 2, 303-306. “Traceless Solid-Phase Synthesis of Chiral 3-Aryl β-Amino Acid-Containing Peptides Using a Side Chain Tethered β-Amino Acid Building Block.”
174. Wang, X.; Silverman, R. B. Bioorg. Med. Chem. 2000, 8, 1645-1651. “Monoamine Oxidase-Catalyzed Oxidation of endo, endo-2-Amino-6-[(Z)-2′-phenyl]ethenylbicyclo[2.2.1]heptane, a Potential Probe for a Radical Cation Intermediate.”
175. Tierney, D. L.; Huang, H.; Martásek, P.; Roman, L. J.; Silverman, R. B.; Masters, B. S. S.; Hoffman, B. M. J. Am. Chem. Soc. 2000, 122, 5405-5406. “ENDOR Studies of L-Arginine and NG-Hydroxy-L-Arginine Bound to All Three Holo-Nitric Oxide Synthase Isozymes.”
176. Huang, H.; Martásek, P.; Roman, L. J.; Silverman, R. B. J. Med. Chem. 2000, 43, 2938-2945. “Synthesis and Evaluation of Peptidomimetics as Selective Inhibitors and Active Site Probes of Nitric Oxide Synthases.”
177. Tierney, D. L.; Huang, H.; Martásek, P.; Roman, L. J.; Silverman, R. B.; Hoffman, B. M. J. Am. Chem. Soc. 2000, 122, 7869-7875. “ENDOR Spectroscopic Evidence for the Geometry of Binding of retro-inverso-Nω-Nitroarginine-Containing Dipeptide Amides to Neuronal Nitric Oxide Synthase.”
178. Hah, J. M.; Roman, L. J.; Silverman, R. B. Bioorg. Med. Chem. 2000, 8, 1931-1936. “Deuterium Isotope Effects and Product Studies for the Oxidation of Nω-Allyl-L-arginine and Nω-Allyl-Nω-hydroxy-L-arginine by Neuronal Nitric Oxide Synthase.”
179. Lee, Y.; Silverman, R. B. Organic Lett. 2000, 2, 3743-3746. “Rapid, High-Yield, Solid-Phase Synthesis of the Antitumor Antibiotic Sansalvamide A Using a Side-Chain-Tethered Phenylalanine Building Block.”
180. Lee, Y.; Martásek, P.; Roman, L. J.; Silverman, R. B. Bioorg. Med. Chem. Lett. 2000, 10, 2771-2774 “1-H-Pyrazole-1-carboxamidines: New Inhibitors of Nitric Oxide Synthase.”
181. Mitchell, D. J.; Nikolic, D.; Rivera, E.; Sablin, S. O.; Choi, S.; van Breemen, R. B.; Singer, T. P.; Silverman, R. B. Biochemistry 2001, 40, 5447-5456. “Spectrometric Evidence for the Flavin-1-phenylcyclopropylamine Inactivator Adduct with Monoamine Oxidase N.”
182. Huang, H.; Martásek, P.; Roman, L. J.; Silverman, R. B. J. Enzyme Inhib. 2001, 16, 233-239. “Synthesis and Evaluation of Dipeptide Amides Containing Nω-Nitroarginine and D-2,4-Diaminobutyric Acid as Inhibitors of Neuronal Nitric Oxide Synthase.”
183. Huang, H.; Hah, J.-M.; Silverman, R. B. J. Am. Chem. Soc. 2001, 123, 2674-2676. “Mechanism of Nitric Oxide Synthase. Evidence that Direct Hydrogen Atom Abstraction from the O-H Bond of NG-Hydroxyarginine is Not Relevant to the Mechanism.”
184. Mitchell, D. J.; Nikolic, D.; van Breemen, R. B.; Silverman, R. B. Bioorg. Med. Chem. Lett., 2001, 11, 1757-1760. “Inactivation of Monoamine Oxidase B by 1-Phenylcyclopropylamine: Mass Spectral Evidence for the Flavin Adduct.”
185. Mitchell, D. J.; Nikolic, D.; Jang, M.-H.; van Breemen, R. B.; Hille, R.; Silverman, R. B. Biochemistry 2001, 40, 8523-8530. “Inactivation of C30A Trimethylamine Dehydrogenase by N-Cyclopropyl-α-methylbenzylamine, 1-Phenylcyclopropylamine, and Phenylhydrazine.”
186. Lee, Y.; Silverman, R. B. Tetrahedron 2001, 57, 5339-5352. “Silicon-Based Aromatic Transferring Linkers for Traceless Solid-Phase Synthesis of Aryl-, Polyaryl-, and Heteroaryl-Containing Compounds.”
187. Hah, J.-M.; Roman, L. J.; Martásek, P.; Silverman, R. B. J. Med. Chem. 2001, 44, 2667-2670. “Reduced Amide Bond Peptidomimetics. (4S)-N-(4-Amino-5-[aminoalkyl]aminopentyl)-N‘-nitroguanidines, Potent and Highly Selective Inhibitors of Neuronal Nitric Oxide Synthase.”
188. Gómez-Vidal, J. A.; Forrester, M. T.; Silverman, R. B. Organic Lett. 2001, 3, 2477-2479. “Mild and Selective Sodium Azide-Mediated Cleavage of p-Nitrobenzoic Esters.”
189. Gómez-Vidal, J. A.; Silverman, R. B. Organic Lett. 2001, 3, 2481-2484. “Short, Highly Efficient Syntheses of 3-Azido- and 4-Azidoproline Derivatives and Their Precursors.”
190. Choi, S.; Storici, P.; Schirmer, T.; Silverman, R. B. J. Am. Chem. Soc. 2002, 124, 1620-1624. “Design of a Conformationally-Restricted Analogue of the Antiepilepsy Drug Vigabatrin that Directs its Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase.”
191. Choi, S.; Silverman, R. B. J. Med. Chem. 2002, 45, 4531-4539. “Inactivation and Inhibition of γ-Aminobutyric Acid Aminotransferase by Conformationally-Restricted Vigabatrin Analogues.”
192. Lu, X.; Rodriguez, M.; Ji, H.; Silverman, R. B.; Vintém, A. P. B.; Ramsay, R. R. “Irreversible Inactivation of Mitochondrial Monoamine Oxidases” In Flavins and Flavoproteins 2002: Proceedings of the 14th International Symposium; Chapman, S. K.; Perham, R. N.; Scrutton, N. S., Eds.; Rudolf Weber: Berlin, Germany, 2002; pp 817-830.
193. Gu, W.; Liu, S.; Silverman, R. B. Organic Lett. 2002, 4, 4171-4174. “Solid-Phase, Pd-Catalyzed, Silicon-Aryl Carbon Bond Formation. Synthesis of Sansalvamide A Peptide.”
194. Lee, Y.; Ling, K.-Q.; Lu, X.; Silverman, R. B.; Shepard, E. M.; Dooley, D. M.; Sayre, L. M. J. Am. Chem. Soc. 2002, 124, 12135-12143. “3-Pyrrolines are Mechanism-Based Inactivators of the Quinone-Dependent Amine Oxidases but Only Substrates of the Flavin-Dependent Amine Oxidases.”
195. Nandi, D.; Lightcap, E. S.; Koo, Y. K.; Lu, X.; Quancard, J.; Silverman, R. B. Int. J. Biochem. Cell Biol., 2003, 35, 1085-1097. “Purification and Inactivation of 3-Hydroxyanthranilic Acid 3,4-Dioxygenase from Beef Liver.”
196. Gu, W.; Silverman, R. B. Organic Lett. 2003, 5, 415-418. “New Stable Backbone Linker Resins for Solid-Phase Peptide Synthesis.”
197. Hah, J.-M.; Martásek, P.; Roman, L. J.; Silverman, R. B. J. Med. Chem. 2003, 46, 1661-1669.”Aromatic Reduced Amide Bond Peptidomimetics as Selective Inhibitors of Neuronal Nitric Oxide Synthase.”
198. Lu, X.; Rodríguez, M.; Gu, W.; Silverman, R. B. Bioorg. Med. Chem. 2003, 11, 4423-4430. “Inactivation of Mitochondrial Monoamine Oxidase B by Methylthio-Substituted Benzylamines.”
199. Lu, X.; Nikolic, D.; Mitchell, D. J.; van Breemen, R. B.; Mersfelder, J. A.; Hille, R.; Silverman, R. B. Bioorg. Med. Chem. Lett. 2003, 13, 4129-4132 . “A Mechanism for Substrate-Induced Formation of 6-Hydroxyflavin Mononucleotide Catalyzed by C30A Trimethylamine Dehydrogenase.”
200. Gu, W.; Silverman, R. B. J. Org. Chem. 2003, 68, 8774-8779. “Solid-Phase Total Synthesis of Scytalidamide A.”
201. Ji, H.; Li, H.; Flinspach, M.; Poulos, T. L.; Silverman, R. B. J. Med. Chem., 2003, 46, 5700-5711. “Computer Modeling of Selective Regions in the Active Site of Nitric Oxide Synthases: Implication for the Design of Isoform-Selective Inhibitors.”
202. Pan, Y.; Qiu, J.; Silverman, R. B. J. Med. Chem. 2003, 46, 5292-5293. “Design, Synthesis, and Biological Activity of a Difluoro-substituted, Conformationally-rigid Vigabatrin Analogue As a Potent γ-Aminobutyric Acid Aminotransferase Inhibitor.”
203. Flinspach, M.; Li, H.; Jamal, J.; Yang, W.; Huang, H.; Hah, J.-M.; Gomez-Vidal, J. A.; Litzinger, E. A.; Silverman, R. B.; Poulos, T. L. Nature (Struct. Mol. Biol.) 2004, 11, 54-59. “Structural Basis for Dipeptide Amide Isoform-Selective Inhibition of Neuronal Nitric Oxide Synthase.”
204. Fu, M.; Silverman, R. B. Bioorg. Med. Chem. Lett. 2004, 14, 203-206. “Inactivation of γ-Aminobutyric Acid Aminotransferase by (S)-4-Amino-4,5-dihydro-2-furancarboxylic Acid Does Not Proceed by the Expected Aromatization Mechanism.”
205. Storici, P.; De Biase, D.; Bossa, F.; Bruno, S.; Mozzarelli, A.; Peneff, C.; Silverman, R. B.; Schirmer, T. J. Biol. Chem. 2004, 279, 363-373. “Structures of GABA Aminotransferase, a Pyridoxal 5′-Phosphate and [2Fe-2S] Cluster Containing Enzyme, Complexed with the Antiepilepsy Drug Vigabatrin and with γ-Ethynyl GABA.”
206. Gómez-Vidal, J. A.; Martásek, P.; Roman, L. J.; Silverman, R. B. J. Med. Chem. 2004, 47, 703-710. “Potent and Selective Conformationally-Restricted Neuronal Nitric Oxide Synthase Inhibitors.”
207. Wang, Z.; Silverman, R. B. J. Enz. Inhib. Med. Chem. 2004, 19, 293-301. “Synthesis of Cyclopropane Isosteres of the Antiepilepsy Drug Vigabatrin and Evaluation of their Inhibition of GABA Aminotransferase.”
208. Flinspach, M.; Li, H.; Jamal, J.; Yang, W.; Huang, H.; Silverman, R. B.; Poulos, T. L. Biochemistry 2004, 43, 5181-5187. “Structures of the Neuronal and Endothelial NOS Heme Domain with D-Nitroarginine-containing Dipeptide Inhibitors Bound.”
209. Schering, C. A.; Zhong, B.; Woo, J. C. G.; Silverman, R. B. Bioconj. Chem. 2004, 15, 673-676. “Poly(ethylene glycol)-Supported Enzyme Inactivators. Efficient Identification of the Site of Covalent Attachment to α-Chymotrypsin by PEG-TPCK.”
210. Pan, Y.; Calvert, K.; Silverman, R. B. Bioorg. Med. Chem. 2004, 12, 5719-5725. “Conformationally-Restricted Vigabatrin Analogues as Irreversible and Reversible Inhibiors of γ-Aminobutyric Acid Aminotransferase.”
211. Storici, P.; Qiu, J.; Schirmer, T.; Silverman, R. B. Biochemistry 2004, 43, 14057-14063. “Mechanistic Crystallography. Mechanism of Inactivation of γ-Aminobutyric Acid Aminotransferase by (1R,3S,4S)-3-Amino-4-fluorocyclopentane-1-carboxylic Acid as Elucidated by Crystallography.”
212. Westerheide, S. D.; Bosman, J. D.; Mbadugha, B. N. A.; Kawahara, T. L. A.; Matsumoto, G.; Gu, W.; Kim, S.; Devlin, J. P.; Silverman, R. B.; Morimoto, R. I. J. Biol. Chem. 2004, 279, 56053-56060. “Celastrols as Inducers of the Heat Shock Response and Cytoprotection.”
213. Zhu, Y.; Nikolic, D.; Van Breemen, R. B.; Silverman, R. B. J. Am. Chem. Soc. 2005, 127, 858-868. “Mechanism of Inactivation of Inducible Nitric Oxide Synthase by Amidines. Irreversible Enzyme Inactivation without Inactivator Modification.”
214. Erdal, E. P.; Litzinger, E. A.; Seo, J.; Zhu, Y.; Ji, H.; Silverman, R. B. Curr. Topics Med. Chem. 2005, 5, 603-624. “Selective Neuronal Nitric Oxide Synthase Inhibitors.”
215. Vintém, A. P. B.; Price, N. T.; Silverman, R. B.; Ramsay, R. R. Bioorg. Med. Chem. 2005, 13, 3487-3495. “Mutation of Surface Cysteine 374 to Alanine in Monoamine Oxidase A Alters Substrate Turnover and Inactivation by Cyclopropylamines.”
216. Liu, S.; Gu, W.; Lo, D.; Ding, X.-Z.; Ujiki, M.; Adrian, T. E.; Soff, G. A.; Silverman, R. B. J. Med. Chem. 2005, 48, 3630-3638. “N– Methylsansalvamide A Peptide Analogues. Potent New Antitumor Agents.”
217. Li, H.; Flinspach, M. L.; Igarashi, J.; Jamal, J.; Yang, W.; Gomez-Vidal, J. A.; Litzinger, E. A.; Huang, H.; Erdal, E. P.; Silverman, R. B.; Poulos, T. L. Biochemistry 2005, 44, 15222-15229. “Exploring the Binding Conformations of Bulkier Dipeptide Amide Inhibitors in Constitutive Nitric Oxide Synthases.”
218. Crittenden, D. L.; Park, A.; Qiu, J.; Silverman, R. B.; Duke, R. K.; Johnston, G. A. R.; Jordan, M. J. T.; Chebib, M. Bioorg. Med. Chem. 2006, 14, 447-455. “Enantiomers of cis-constrained and flexible 2-substituted GABA analogues exert opposite effects at recombinant GABAC receptors.”
219. Yuan, H.; Silverman, R. B. Bioorg. Med. Chem. 2006, 14, 1331-1338. “New Substrates and Inhibitors of γ-Aminobutyric Acid Aminotransferase Containing Bioisosteres of the Carboxylic Acid Group: Design, Synthesis, and Biological Activity.”
220. Ujiki, M. B.; Milam, B.; Ding, X.-Z.; Roginsky, A. B.; Salabat, M. R.; Talamonti, M. S.; Bell, R. H.; Gu, W.; Silverman, R. B.; Adrian, T. E. Biochem. Biophys. Res. Commun. 2006, 340, 1224-1228. “A Novel Peptide Sansalvamide A Analogue Inhibits Pancreatic Cancer Cell Growth Through G0/G1 Cell Cycle Arrest.”
221. Wang, Z.; Silverman, R. B. Biochemistry 2006, 14, 2242-2252. “Syntheses and Evaluation of Fluorinated Conformationally Restricted Analogues of GABA as Potential Inhibitors of GABA Aminotransferase.”
222. Litzinger, E. A.; Martásek, P.; Roman, L. J.; Silverman, R. B. Bioorg. Med. Chem. 2006, 14, 3185-3198. “Design, Synthesis, and Biological Testing of Potential Heme-Coordinating Nitric Oxide Synthase Inhibitors.”
223. Gu, W.; Nusinzon, I.; Smith, R. D. Jr.; Horvath, C. M.; Silverman, R. B. Bioorg. Med. Chem. 2006, 14, 3320-3329. “Carbonyl- and Sulfur-Containing Analogs of Suberoylanilide Hydroxamic Acid. Potent Inhibition of Histone Deacetylases.”
224. Mbadugha, B. N. A.; Seo, J.; Ji, H.; Martásek, P.; Roman, L. J.; Shea, T. M.; Silverman, R. B. Bioorg. Med. Chem.2006, 14, 3681-3690. “Hydroxyl-terminated Peptidomimetic Inhibitors of Neuronal Nitric Oxide Synthase.”
225. Seo, J.; Silverman, R. B. Tetrahedron Lett., 2006, 47, 4069-4073. “Synthesis of Arginine-containing Hydroxamate Dipeptidomimetics.”
226. Lawton, G. L.; Ji, H.; Silverman, R. B. Tetrahedron Lett., 2006, 47, 6113-6115. “Remote Protection Prevents Unwanted Cyclizations with 2-Aminopyridines.”
227. Ji, H.; Gómez-Vidal, J. A.; Martásek, P.; J. Roman, L. J.; Silverman, R. B. J. Med. Chem., 2006, 49, 6254-6263. “Conformationally-Restricted Dipeptide Amides as Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors.”
228. Lu, H.; Silverman, R. B. J. Med. Chem., 2006, 49, 7404-7412. “Fluorinated Conformationally-Restricted γ-Aminobutyric Acid Aminotransferase Inhibitors.”
229. Wang, Z.; Yuan, H.; Silverman, R. B. Biochemistry, 2006, 45, 14513-14522. “(±)-(1S,2R,5S)-5-Amino-2-fluorocyclohex-3-ene Carboxylic Acid, A Potent GABA Aminotransferase Inactivator that Irreversibly Inhibits through an Elimination-Aromatization Pathway.”
230. Zhu, Y.; Silverman, R. B. J. Org. Chem., 2007, 72, 233-239. “Electronic Effects of Peripheral Substituents on Porphyrin Meso-Positions.”
231. Seo, J.; Igarashi, J.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. J. Med. Chem. 2007, 50, 2089-2099. “Structure-Based Design and Synthesis of Nw-Nitro-L-Arginine-Containing Peptidomimetics as Selective Inhibitors of Neuronal Nitric Oxide Synthase. Displacement of the Heme Structural Water.”
232. Seo, J.; Martásek, P.; Roman, L. J.; Silverman, R. B. Bioorg. Med. Chem. 2007, 15, 1928-1938. “Selective L-Nitroargininylaminopyrrolidine and L-Nitroargininylaminopiperidine Neuronal Nitric Oxide Synthase Inhibitors.”
233. Yuan, H.; Silverman, R. B. Bioorg. Med. Chem. Lett. 2007, 17, 1651-1654.”Structural Modifications of (1S,3S)-3-Amino-4-Difluoromethylenecyclopentanecarboxylic Acid, a Potent Irreversible Inhibitor of GABA Aminotransferase.”
234. Zhu, Y.; Silverman, R. B. Org. Lett. 2007, 9, 1195-1198. “Model Studies for Heme Oxygenase-Catalyzed Porphyrin Meso Hydroxylation.”
235. Gu, W.; Cueto, M.; Jensen, P. R.; Fenical, W.; Silverman, R. B. Tetrahedron 2007, 63, 6535-6541. “Microsporins A and B: new histone deacetylase inhibitors from the marine-derived fungus Microsporum cf. gypseum and the solid-phase synthesis of microsporin A.”
236. Erdal, E. P.; Martásek, P.; Linda J. Roman, L. J.; Silverman, R. B. Bioorg. Med. Chem. 2007, 15, 6096-6108. “Hydroxyethylene Isosteres of Selective Neuronal Nitric Oxide Synthase Inhibitors.”
237. Clift, M.; Ji, H.; Deniau, G. P.; O’Hagan, D.; Silverman, R. B. Biochemistry 2007, 46(48), 13819-13828. “The Enantiomers of 4-Amino-3-fluorobutanoic Acid as Substrates for g-Aminobutyric Acid Aminotransferase. Conformational Probes for GABA Binding.”
238. Liu, D.; Pozharski, E.; Lepore, B. W.; Fu, M.; Silverman, R. B.; Petsko, G. A.; Ringe, D. Inactivation of Escherichia coli L-Aspartate Aminotransferase by (S)-4-Amino-4,5-dihydro-2-thiophenecarboxylic Acid Reveals A Tale of Two Mechanisms. Biochemistry 2007, 46(37), 10517-10527.
239. Silverman, R. B. Angew. Chem. Int. Ed. 2008, 47, 3500-3504. “From Basic Science to Blockbuster Drug. The Discovery of Lyrica.”
240. Clift, M. D.; Silverman, R. B. Bioorg. Med. Chem. Lett. 2008, 18 (10), 3122-3125. “Synthesis and Evaluation of Novel Aromatic Substrates and Competitive Inhibitors of GABA Aminotransferase.”
241. Ji, H.; Stanton, B. Z.; Igarashi, J.;, Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. J. Am. Chem. Soc. 2008, 130(12), 3900-3914. “Minimal Pharmacophoric Elements and Fragment Hopping, an Approach Directed at Molecular Diversity and Isozyme Selectivity. Design of Selective Neuronal Nitric Oxide Synthase Inhibitors.”
242. Zhu, Y.; Silverman, R. B. Biochemistry 2008, 47(8), 2231-2243. “Revisiting Heme Mechanisms. A Perspective on the Mechanisms of Nitric Oxide Synthase (NOS), Heme Oxygenase (HO), and Cytochrome P450s (CYP450s).”
243. Trott, A.; West, J. D.; Klaic, L.; Westerheide, S. D.; Silverman, R. B.; Morimoto, R. I.; Morano, K. A. Mol. Biol. Cell 2008, 19(3), 1104-1112. “Activation of Heat Shock and Antioxidant Responses by the Natural Product Celastrol: Transcriptional Signatures of a Thiol-targeted Molecule.”
244. Silverman, R. B., Enzyme Inhibition In Wiley Encyclopedia of Chemical Biology; John Wiley & Sons, Hoboken, 2009, Volume 1, pp 663-681.
245. Ji,H.; Tan,S.; Igarashi,J.; Li,H.; Derrick,M.; Martásek,P.; Roman,L. J.; Vásquez-Vivar,J.; Poulos,T. L.; Silverman, R. B. Ann. Neurol. 2009, 65, 209-217. “Selective Neuronal Nitric Oxide Synthase Inhibitors for Prevention of Cerebral Palsy.”
246. Ji, H.; Erdal, E. P.; Litzinger, E. A.; Seo, J.; Zhu, Y.; Xue, F.; Fang, J.; Huang, J.; Silverman, R. B. Frontiers in Medicinal Chemistry, Reitz, A. B.; Choudhary, M. I.; Atta-ur-Rahman, Editors; Bentham Science Publishers, Volume 5, 2009, 842-882. “Selective Neuronal Nitric Oxide Synthase Inhibitors.”
247. Ji,H.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. J. Med. Chem. 2009, 52 (3), 779–797. ” Discovery of Highly Potent and Selective Inhibitors of Neuronal Nitric Oxide Synthase by Fragment Hopping.”
248. Silverman, R. B. Acc. Chem. Res. 2009, 42, 439-451. ” Design of Selective Neuronal Nitric Oxide Synthase Inhibitors for the Prevention and Treatment of Neurodegenerative Diseases.”
249. Igarashi, J.; Li, H.; Jamal, J.; Ji, H.; Fang, J.; Lawton, G. R.; Silverman, R. B.; Poulos, T. L. J. Med. Chem. 2009, 52, 2060-2066. “Crystal Structures of Constitutive Nitric Oxide Synthases in Complex with De Novo Designed Inhibitors.”
250. Lawton, G. R.;Ralay Ranaivo, H.; Wing, L. K.; Ji, H.; Xue, F.; Martásek, P.; Roman, L. J.; Watterson, D. M.; Silverman, R. B. Bioorg. Med. Chem. 2009, 17(6), 2371-2380. ” Analogues of 2-aminopyridine-based Selective Inhibitors of Neuronal Nitric Oxide Synthase with Increased Bioavailability.”
251. Fang, J.; Ji,H.; Lawton, G. R.; Xue, F.; Martásek, P.; Roman, L. J.; Silverman, R. B. J. Med. Chem. 2009, 52, 4533-4537. “L337H Mutant of Rat Neuronal Nitric Oxide Synthase Resembles Human Neuronal Nitric Oxide Synthase Toward Inhibitors.”
252. Fang, J.; Silverman, R. B. Anal. Biochem. 2009, 390, 74-78. “A Cellular Model for Screening Neuronal Nitric Oxide Synthase Inhibitors.”
253. Lawton, G. R.; Ji,H.; Martásek, P.; Roman, L. J.; Silverman, R. B. Beilstein J. Org. Chem. 2009, 5, No. 28. “Synthesis and Enzymatic Evaluation of 2- and 4-aminothiazole-based Inhibitors of Neuronal Nitric Oxide Synthase.”
254. Derrick, M.; Drobyshevsky, A.; Ji, X.; Chen, L.; Yang, Y.; Ji, H.; Silverman, R. B.; Tan, S. Int. J. Devel. Neurosci. 2009, in press. “Hypoxia-ischemia causes persistent movement deficits in a perinatal rabbit model of cerebral palsy: assessed by a new swim test.”
255. Silverman, R. B.; Lawton, G. R.; Ralay Ranaivo, H.; Seo, J.; Watterson, D. M. Effect of Potential Amine Prodrugs of Selective Neuronal Nitric Oxide Synthase Inhibitors on Blood-Brain Barrier Penetration. Bioorg. Med. Chem. 2009, 17, 7593-7605.
256. Xue, F.; Gu, W.; Silverman, R. B. A Concise Route to the Chiral Pyrrolidine Core for Inhibitors of Neuronal Nitric Oxide Synthase. Org. Lett. 2009, 11 (22), 5194–5197.
257. Delker, D. L.; Ji, H.; Li, H.; Jamal, J.; Fang, J.; Xue, X.; Silverman, R. B.; Poulos, T. L. Unexpected Binding Modes of Nitric Oxide Synthase Inhibitors Effective in the Prevention of Cerebral Palsy, J. Am. Chem. Soc. 2010, 132, 5437–5442.
258. Martell, J. D.; Li, H.; Doukov, T.; Martásek, P.; Roman, L. J.; Soltis, M.; Poulos, T. L.; Silverman, R. B. Heme-Coordinating Inhibitors of Neuronal Nitric Oxide Synthase. Iron-Thioether Coordination is Stabilized by Hydrophobic Contacts Without Increased Inhibitor Potency. J. Am. Chem. Soc. 2010, 132(2), 798–806.
259. Kudoh, T.; Park, C. S.; Lefurgy, S. T.; Sun, M.; Michels, T.; Leyh, T. S.; Silverman, R. B. Mevalonate Analogues as Substrates of Enzymes in the Isoprenoid Biosynthetic Pathway of Streptococcus pneumoniae. Bioorg. Med. Chem. 2010, 18, 1124-1134.
260. Xue, F.; Fang, J.; Lewis, W. W.; Martásek, P.; Roman, L. J.; Silverman, R. B. Potent and selective neuronal nitric oxide synthase inhibitors with improved cellular permeability. Bioorg. Med. Chem. Lett. 2010, 20, 554-557.
261. Heiferman, M. J.; Salabat, M. R.; Ujiki, M. B.; Strouch, M. J.; Cheon, E. C.; Silverman, R. B.; Bentrim, D. J. Sansalvamide induces pancreatic cancer growth arrest through changes in the cell cycle. Anticancer Res. 2010, 30, 73.
262. Xue, F.; Silverman, R. B. An Alkoxide Anion Triggered tert-Butyloxycarbonyl Group Migration. Mechanism and Application. Tetrahedron Lett. 2010, 51, 2536-2538.
263. Chang, C.-C.; Cao, S.; Kang, S.; Kai, L.; Tian, X.; Pandey, P.; Fernandez Dunne, S.; Luan, C.-H.; Surmeier, D. J.; Silverman, R. B. Antagonism of 4-substituted 1,4-dihydropyridine-3,5-dicarboxylates toward voltage-dependent L-type Ca2+ channels CaV1.3 and CaV1.2. Bioorg. Med. Chem 2010, 18, 3147-3158.
264. Lepore, B. W.; Liu, D.; Peng, Y.; Fu, M.; Yasuda, C.; Manning, J. M.; Silverman, R. B.; Ringe, D. Chiral discrimination among aminotransferases: inactivation by 4-amino-4,5-dihydrothiophenecarboxylic acid. Biochemistry 2010 49(14), 3138-47.
265. Lefurgy, S. T.; Rodriguez, S. B.; Park, C. S.; Cahill, S.; Silverman, R. B.; Leyh, T. S. Probing ligand-binding pockets of the mevalonate pathway enzymes from Streptococcus pneumoniae. J Biol. Chem. 2010, 285(27), 20654-63.
266. Xue, F.; Huang, J.; Ji, H.; Li, H.; Martasek, P.; Roman, L. J.; Poulos, T. P.; Silverman, R. B. Structure-based design, synthesis, and biological evaluation of lipophlic-tailed monocationic inhibitors of neuronal nitric oxide synthase. Bioorg. Med. Chem. 2010, 18, 6526-6261.
267. Xue, F.; Li, H.; Fang, J.; Roman, L. J.; Martasek, P.; Poulos T.L.; Silverman, R. B. Peripheral but crucial: a hydrophobic pocket (Tyr706, Leu337, and Met336) for potent and selective inhibition of neuronal nitric oxide synthase. Bioorg. Med. Chem. Lett. 2010, 20, 6258-6261.
268. Xue, F.; Li, H.; Delker, S.; Fang, J.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Potent, Highly Selective, and Orally Bioavailable Gem-Difluorinated Monocationic Inhibitors of Neuronal Nitric Oxide Synthase, J. Am. Chem. Soc. 2010, 132(40), 14229-14238.
269. Ji, H.; Delker, S. L.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T.P.; Silverman, R. B. Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives. J. Med. Chem. 2010, 53, 7804-7824.
270. Delker, S. L.; Xue, F.; Li, H.; Jamal, J.; Silverman, R. B.; Poulos, T.P. Role of zinc in isoform selective inhibitors of neuronal nitric oxide synthase. Biochemistry 2010, 49, 10803-10810.
271. Liu, D.; Pozharski, E.; Fu, M.; Silverman, R. B.; Ringe, D. Mechanism of Inactivation of Escherichia coli Aspartate Aminotransferase by (S)-4-Amino-4,5-dihydro-2-furancarboxylic Acid. Biochemistry 2010, 49(49), 10507-10515.
272. Chen, T.; Benmohamed, R.; Arvanites, A. C.; Ranaivo, H. R.; Morimoto, R. I.; Ferrante, R. J.; Watterson, D. M.; Kirsch, D. R.; Silverman, R. B. Arylsulfanyl Pyrazolones Block Mutant SOD1-G93A Aggregation. Potential Application for the Treatment of Amyotrophic Lateral Sclerosis. Bioorg. Med. Chem. 2010, 19, 613-622.
273. Yu, L.; Derrick, M.; Ji, H.; Silverman, R. B.; Whitsett, J.; Vasquez-Vivar, J.; Tan, S. Neuronal nitric oxide synthase inhibition prevents cerebral palsy following hypoxia-ischemia in fetal rabbits: Comparison between JI-8 and 7-nitroindazole. Dev. Neurosci. 2011, 33, 312-319.
274. Benmohamed, R.; Arvanites, A. C.; Kim, J.; Ferrante, R. J.; Silverman, R. B.; Morimoto, R. I.; Kirsch, D. R. Identification of compounds protective against G93A SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotroph. Lat. Scler. 2011, 12, 87-96.
275. Xue, F.; Delker, S. L.; Li, H.; Fang, J.; Martásek, P.; Roman, L. J.; Poulos, T.P.; Silverman, R. B. Symmetric double-headed aminopyridines. A novel strategy for potent and membrane-permeable inhibitors of neuronal nitric oxide synthase. J. Med. Chem. 2011, 54, 2039-2048.
276. Rao, S.; Lin, Z.; Drobyshevsky, A.; Chen, L.; Ji, X.; Ji, H.; Yang, Y.; Yu, L.; Derrick, M.; Silverman, R. B.; Tan, S. Involvement of Neuronal Nitric Oxide Synthase in Ongoing Fetal Brain Injury Following Near-Term Rabbit Hypoxia-Ischemia. Dev. Neurosci. 2011, 33, 288-298.
277. Xia, G.; Benmohamed, R.; Kim, J.; Arvanites, A. C.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R.; Silverman, R. B. Pyrimidine-2,4,6-trione Derivatives and Their Inhibition of Mutant SOD1-dependent Protein Aggregation. Toward a Treatment for Amyotrophic Lateral Sclerosis (ALS). J. Med. Chem. 2011, 54, 2409-2421.
278. Doukov, T.; Li, H.; Sharma, A.; Martell, J. D.; Soltis, M.; Silverman, R. B.; Poulos, T. L.; Temperature dependent spin crossover in neuronal nitric oxide synthase bound with the heme-coordinating thioether inhibitors. J. Am. Chem. Soc. 2011, 133, 8326-8334.
279. Xue, F.; Kraus, J. M.; Jansen Labby, K.; Ji, H.; Mataka, J.; Xia, G.; Li, H.; Delker, S. L.; Roman, L. J.; Martásek, P.; Poulos, T. L.; Silverman, R. B. Improved Synthesis of Chiral Pyrrolidine Inhibitors and Their Binding Properties to Neuronal Nitric Oxide Synthase. J. Med. Chem. 2011, 54, 6399-6403.
280. Gu, W.; Silverman, R. B. Synthesis of (S)-2-Boc-Amino-8-(R)-(tert-butyldimethylsilanyloxy)decanoic acid, a Precursor to the Unusual Amino Acid Residue of the Anticancer Agent Microsporin B Tetrahedron Lett. 2011, 52, 5438-5440.
281. Gu, W.; Silverman, R. B. Stereospecific Total Syntheses of Proteasome Inhibitors Omuralide and Lactacystin. J. Org. Chem. 2011, 76, 8287-8293.
282. Watanabe, M.; Yamaguchi, K.; Tang, W.; Yoshida, K.; Silverman, R. B.; Arisawa, M.; Shuto, S. Synthesis of a series of 3,4-methanoarginines as side-chain conformationally-restricted analogues of arginine. Bioorg. Med. Chem. 2011, 19, 5984-5988.
283. Klaic, L.; Trippier, P.; Mishra, R.; Morimoto, R. I.; Silverman, R. B. Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol. J. Am. Chem. Soc., 2011, 133(49), 19634-19637.
284. Pan, Y.; Gerasimov, M. R.; Kvist, T.; Wellendorph, P.; Madsen, K. K.; Pera, E.; Lee, H.; Schousboe, A.; Chebib, M.; Bräuner-Osborne, H.; Craft, C. M.; Brodie, J. D.; Schiffer, W. K.; Dewey, S. L.; Miller, S. R.; Silverman, R. B. CPP-115, a Potent g-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Cocaine Addiction. J. Med. Chem. 2012, 55, 357-366.
285. Zhang, W.; Benmohamed, R.; Arvanites, A. C.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R.; Silverman, R. B. Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. Bioorg. Med. Chem. 2012, 20, 1029-1045.
286. Ji, H.; Jing, Q.; Huang, J.; Silverman, R. B. Acid-Facilitated Debenzylation of N-Boc, N-Benzyl Double Protected 2-Aminopyridinomethylpyrrolidine Derivatives. Tetrahedron 2012, 68, 1359-1366.
287. Chen, T.; Benmohamed, R.; Kim, J.; Smith, K.; Amante, D.; Morimoto, R. I.; Kirsch, D. R.; Ferrante, R. J.; Silverman, R. B. ADME-Guided Design and Synthesis of Aryloxanyl Pyrazolone Derivatives to Block Mutant SOD1 Cytotoxicity and Protein Aggregation: Potential Application for the Treatment of Amyotrophic Lateral Sclerosis. J. Med. Chem. 2012, 55, 515-527.
288. Kraus, J. M.; Gits, H.; Silverman, R. B. High yielding allylation of a chiral secondary alcohol containing base sensitive functional groups. Tetrahedron Lett. 2012 53, 1319-1322.
289. Silverman, R. B. The 2011 E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances: (1S,3S)-3-Amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA Aminotransferase Inactivator and New Treatment for Drug Addiction and Infantile Spasms. J. Med. Chem. 2012, 55, 567-575.
290. Jansen Labby, K.; Xue, F.; Kraus, J. M.; Ji, H.; Mataka, J.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Intramolecular Hydrogen Bonding: A Potential Strategy for More Bioavailable Inhibitors of Neuronal Nitric Oxide Synthase, Bioorg. Med. Chem. 2012, 20, 2435-2443.
291. Choi, S. H.; Quinti, L.; Kazantsev, A. G.; Silverman, R. B. 3-(N-Arylsulfamoyl)benzamides, Inhibitors of Human Sirtuin Type 2 (SIRT2). Bioorg. Med. Chem. Lett. 2012, 22, 2789-2793.
292. Klaic, L.; Morimoto, R. I.; Silverman, R. B. Celastrol Analogs as Inducers of the Heat Shock Response. Design and Synthesis of Affinity Probes for the Identification of Protein Targets. ACS Chem. Biol. 2012, 7, 928-937.
293. Zhang, Y.; Silverman, R. B. Direct amination of gamma-halo-beta-ketoesters with anilines. J. Org. Chem. 2012, 77, 3462-3467.
294. Huang, H.; Ji, H.; Li, H.; Jing, Q.; Jansen Labby, K.; Martásek, P.; Roman, L. J.; Poulos, T. P.; Silverman, R. B. Selective Monocationic Inhibitors of Neuronal Nitric Oxide Synthase. Binding Mode Insights from Molecular Dynamics Simulations. J. Am. Chem. Soc. 2012, 134, 11559-11572.
295. Zhang, Y.; Benmohamed, R.; Zhang, W.; Kim, J.; Edgerly, C.; Zhu, Y.; Morimoto, R. I.; Ferrante, R. J.; Kirsch, D. R.; Silverman, R. B. Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of ALS. ACS Med. Chem. Lett. 2012, 3, 584-587.
296. Kang, S.; Cooper, G.; Dunne, S. F.; Dusel, B.; Luan, C.-H.; Surmeier, D. J.; Silverman, R. B. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson’s disease. Nature Commun. 2012, 3, 1146.
297. Drobyshevsky, A.; Yu, L.; Yang, Y.; Khalid, S.; Luo, K.; Jiang, R.; Ji, H.; Derrick, M.; Kay, L.; Silverman, R. B.; Tan, S.Antenatal Insults Modify Newborn Olfactory Function By Nitric Oxide Produced From Neuronal Nitric Oxide Synthase. Exp. Neurol. 2012, 237, 427-434.
298. Trippier, P.; Benmohamed, R.; Kirsch, D. R.; Silverman, R. B. Substituted pyrazolones require N2 hydrogen bond donating ability to protect against cytotoxicity from protein aggregation of mutant super-oxide dismutase 1. Bioorg. Med. Chem. Lett. 2012, 22, 6647-6650.
299. Hawker, D. D.; Silverman, R. B. Synthesis and evaluation of novel heteroaromatic substrates of GABA aminotransferase. Bioorg. Med. Chem. 2012, 20, 5763-5773.
300. Yang, Z.; Misner, B.; Ji, H.; Poulos, T. L.; Silverman, R. B.; Meyskens, F. L.; Yang, S. Targeting nitric oxide (NO) signaling as a novel strategy for the therapy and prevention of human melanoma. Antioxid. Redox Signal. 2013, 1-15.
301. Chopra, V.; Quinti, L.; Kim, J.; Vollor, L.; Kumaraswamy. L.; Edgerly, C.; Cipicchio, P. M.; Lauver, M. A.; Choi, S. H.; Sittampalli, B.; Silverman, R. B.; Ferrante, R. J.; Steven Hersch, S.; Kazantsev, A. G. The Sirtuin 2 Inhibitor AK-7 is Neuroprotective in Huntington Disease Mouse Models, Cell Rep. 2012, 2, 1492-7.
302. Jansen Labby, K.; Li, H.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Methylated Nw-hydroxy-L-arginine analogues as mechanistic probes for the second step of the nitric oxide synthase-catalyzed reaction. Biochemistry 2013, 52, 3062-3073.
303. Zhang, Y.; Silverman, R. B. A novel synthesis of 1-aryl-3-piperidone derivatives. Tetrahedron Lett. 2013, 54, 573-575.
304. Juncosa, Jr., J. I.; Groves, A. P.; Xia, G.; Silverman, R. B. Probing the steric requirements of the g-aminobutyric acid aminotransferase active site with fluorinated analogues of vigabatrin. Bioorg. Med. Chem. 2013, 21, 903-911.
305. Huang, H.; Silverman, R. B. Recent Advances Toward Improving the Bioavailability of Neuronal Nitric Oxide Synthase Inhibitors. Curr. Top. Med. Chem. 2013, 13, 803-812.
306. Li, H.; Xue, F.; Kraus II, J. M.; Ji, H.; Jansen Labby, K.; Mataka, J.; Delker, S. L.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Cyclopropyl- and methyl-containing inhibitors of neuronal nitric oxide synthase. Bioorg. Med. Chem. 2013, 21, 1333-1343.
307. Trippier, P. C.; Jansen Labby, K.; Hawker, D. D.; Mataka, J. J.; Silverman, R. B. Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. J. Med. Chem., 2013, 56, 3121-3147.
308. Zhang, Y.; Benmohamed, R.; Huang, H.; Chen, T.; Voisine, C.; Morimoto, R. I.; Kirsch, D. R.; Silverman, R. B. Arylazanylpyrazolone derivatives as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of amyotrophic lateral sclerosis, J. Med. Chem. 2013, 56, 2665-2675.
309. Huang, H.; Li, H.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Structure-guided design of selective inhibitors of neuronal nitric oxide synthase, J. Med. Chem. 2013, 56, 3024-3032.
310. Kang, S.; Cooper, G.; Dunne, S. F.; Luan, C.-H.; Surmeier, D. J.; Silverman, R. B. Antagonism of L-type Ca2+channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics. Bioorg. Med. Chem. 2013, 21, 4365-4373.
311. Kang, S.; Cooper, G.; Dunne, S. F.; Luan, C.-H.; Surmeier, D. J.; Silverman, R. B. Structure-activity relationship of N,N’-disubstituted pyrimidinetriones as CaV1.3 channel-selective antagonists for Parkinson’s disease. J. Med. Chem. 2013, 56, 4786-4797.
312. Juncosa, J. I.; Lee, H.; Silverman, R. B. Two continuous coupled assays for ornithine-d-aminotransferase. Anal. Biochem. 2013, 440, 145-149.
313. Jing, Q.; Li, H.; Fang, J.; Roman, L. J.; Martásek, P.; Poulos, T. L.; Silverman, R. B. In search of potent and selective inhibitors of neuronal nitric oxide synthase with more simple structures. Bioorg. Med. Chem. 2013, 21, 5323-5331.
314. Huang, H.; Li, H.; Yang, S.; Chreifi, G.; Martásek, P.; Roman, L. J.; Meyskens, F. L.; Poulos, T. L.; Silverman, R. B. Potent and Selective Double-headed Thiophene-2-carboximidamide Inhibitors of Neuronal Nitric Oxide Synthase for the Treatment of Melanoma. J. Med. Chem. 2014, 57, 686-700.
315. Jing, Q.; Li, H.; Chreifi, G.; Roman, L. J.; Martásek, P.; Poulos, T. L.; Silverman, R. B. Chiral linkers to improve selectivity of double-headed neuronal nitric oxide synthase inhibitors. Bioorg. Med. Chem. Lett. 2013, 23, 5674-5679.
316. Holden, J. K.; Li, H.; Jing, Q.; Kang, S.; Richo, J.; Silverman, R. B.; Poulos, T. L. Structural and biological studies on bacterial nitric oxide synthase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 18127-18131.
317. Walia, A.; Kang, S.; Silverman, R. B. Microwave-assisted protection of primary amines as 2,5-dimethylpyrroles and their orthogonal deprotection. J. Org. Chem. 2013, 78, 10931-10937.
318. Drury, P. P.; Davidson, J. O.; van Den Heuij, L.; Tan, S.; Silverman, R. B.; Ji, H.; Blood, A.; Fraser, M.; Bennet, L.; Gunn, A. J. Partial neuroprotection by nNOS inhibition during profound asphyxia in preterm fetal sheep. Exp. Neurol. 2013, 250, 282-292.
319. Jing, Q.; Li, H.; Roman, L. J.; Martásek, P.; Poulos, T. L.; Silverman, R. B. An accessible chiral linker to enhance potency and selectivity of neuronal nitric oxide synthase inhibitors. ACS Med Chem Lett 2014, 5, 56-60.
320. Mukherjee, P.; Cinelli, M. A.; Kang, S.; Silverman, R. B. Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain. Chem. Soc. Rev. 2014, Chem. Soc. Rev. 2014, 43(19), 6814-6838. PMCID: PMC4138306
321. Khanfar, M. A.; Quinti, L.; Wang, H.; Choi, S. H.; Kazantsev, A. G.; Silverman, R. B. Development and characterization of 3-(benzylthio)benzamides as potent and selective SIRT2 inhibitors. Eur. J. Med. Chem. 2014, 76, 414-426.
322. Cinelli, M. A.; Li, H.; Chriefi, G.; Martasek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Simplified 2-aminoquinoline-based scaffold for potent and selective neuronal nitric oxide synthase inhibition. J. Med. Chem. 2014, 57(4), 1513-1530.
323. Drury, P. P; Davidson, J. O.; van den Heuij, L G.; Bennet, L.; Tan, S.; Silverman, R. B.; Ji, H.; Gunn, A. J. nNOS inhibition during profound asphyxia reduces seizure burden and improves survival of striatal phenotypic neurons in preterm fetal sheep. Neuropharmacol. 2014, 83, 62-70.
324. Kang, S.; Tang, W.; Li, H.; Chreifi, G.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Nitric oxide synthase inhibitors that interact with both a heme propionate and tetrahydrobiopterin show high isoform selectivity. J. Med. Chem. 2014, 57 (10), pp. 4382-4396.
325. Trippier, P. C.; Zhao, K. T.; Fox, S. G.; Schiefer, I. T.; Benmohamed, R.; Moran, J.; Kirsch, D. R.; Morimoto, R. I.; Silverman, R. B. Proteasome Activation is a Mechanism for Pyrazolone Small Molecules Displaying Therapeutic Potential in Amyotrophic Lateral Sclerosis. ACS Chem. Neurosci. 2014, 5, 823-829. PMCID: PMC4176317
326. Lee, H.; Juncosa, J. I.; Silverman, R. B. Ornithine aminotransferase vs. GABA aminotransferase. Implications for the design of new anticancer drugs. Med. Res. Rev. 2015, 35, 286-305. PMCID: PMC4415689
327. Davydov, R.; Jansen Labby, K.; Chobot, S. E.; Lukoyanov, D. A.; Crane, B. R.; Silverman, R. B.; Hoffman, B. M. Enzymatic and cryoreduction EPR studies of the hydroxylation of methylated Nw-hydroxy-L-arginine analogues by nitric oxide synthase from Geobacillus stearothermophilus. Biochemistry, 2014, 53 (41), 6511-6519. PMCID: PMC4204881
328. Li, H.; Jamal, J.; Plaza, C.; Pineda, S. H.; Chreifi, G.; Jing, Q.; Cinelli, M. A.; Silverman, R. B.; Poulos, T. L. Structures of human constitutive nitric oxide synthases. Acta Crystallog. D, 2014, D70, 2667-2674. PMCID: PMC4188008
329. Jing, Q.; Li, H.; Roman, L. J.; Martásek, P.; Poulos, T. L.; Silverman, R. B. Combination of chiral linkers with thiophenecarboximidamide heads to improve the selectivity of inhibitors of neuronal nitric oxide synthase. Bioorg. Med. Chem. Lett. 2014, 24, 4504-4510. PMCID: PMC4204799
330. Li, H.; Jamal, J.; Delker, S.; Ji, H.; Jing, Q.; Huang, H.; Kang, S.; Silverman, R. B.; Poulos, T. L. The mobility of a conserved tyrosine residue controls isoform-dependent enzyme-inhibitor interactions in nitric oxide synthases. Biochemistry, 2014, 53, 5272-5279. PMCID: PMC4139154
331. Kang, S.; Watanabe, M.; Jacobs, J.C.; Yamaguchi, M.; Dahesh, S.; Nizet, V.; Leyh, T. S.; Silverman, R. B. Synthesis of mevalonate- and fluorinated mevalonate prodrugs and their in vitro human plasma stability. Eur. J. Med. Chem. 2015, 90, 448-461. PMCID: PMC4291291
332. Chen, X.; Wales, P.; Quinti, L.; Moniot, S.; Herisson, F.; Abdul Rauf, N.; Zuo, F.; Wang, H.; Silverman, R. B.; Ayata, C.; Maxwell, M. M.; Clemens, S.; Schwarzschild, M. A.; Outeiro, T. F.; Kazantsev, A. G. The sirtuin-2 inhibitor AK7 is neuroprotective in models of Parkinson’s disease but not amyotrophic lateral sclerosis and cerebral ischemia. PLOS ONE2015, 10(1):e0116919. doi: 10.1371/journal.pone.0116919. PMCID: PMC4301865
333. Özdinler, P. H.; Silverman, R. B. Treatment of amyotrophic lateral sclerosis: Lessons learned from many failures. ACS Med. Chem. Lett. 2015, 5 (11), 1179-1181. PMCID: PMC4233364
334. Xia, G.; Benmohamed, R.; Morimoto, R. I.; Kirsch, D. R.; Silverman, R. B. Deuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic properties. Bioorg. Med. Chem. Lett. 2014, 24, 5098-5101. PMCID: PMC4250310
335. Mukherjee, P.; Li, H.; Sevrioukova, I.; Chreifi, G.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibitors of neuronal nitric oxide synthase. J. Med. Chem. 2015, 58, 1067–1088. (Editor’s Choice; cover art) PMCID: PMC4329833
336. Holden, J. K.; Kang, S.; Hollingsworth, S. A.; Li, H.; Lim, N.; Chen, S.; Huang, H.; Xue, F.; Tang, W.; Silverman, R. B.; Poulos, T. L. Structure-based design of bacterial nitric oxide synthase inhibitors. J. Med. Chem. 2015, 58, 994-1004. PMCID: PMC4306518
337. Lee, H.; Doud, E. H.; Wu, R.; Sanishvili, R.; Juncosa, J. I.; Liu, D.; Kelleher, N. L.; Silverman, R. B. Mechanism of inactivation of g-aminobutyric acid aminotransferase by (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115). J. Am. Chem. Soc. 2015, 137, 2628-240. PMCID: PMC4353033
338. Le, H. V.; Hawker, D. D.; Wu, R.; Doud, E.; Widom, J.; Sanishvili, R.; Liu, D.; Kelleher, N. L.; Silverman, R. B. Design and mechanism of tetrahydrothiophene-based GABA aminotransferase inactivators. J. Am. Chem. Soc. 2015, 137, 4525-4533. PMCID: PMC4390550
339. Tang, W.; Li, H.; Doud, E. H.; Chen, Y.; Choing, S.; Plaza, C.; Kelleher, N. L.; Poulos, T. L.; Silverman, R. B. Mechanism of inactivation of neuronal nitric oxide synthase by (S)-2-amino-5-(2-(methylthio)acetimidamido)pentanoic acid. J. Am. Chem. Soc. 2015, 137, 5980-5989. PMCID: PMC4431946
340. Tang, W.; Li, H.; Poulos, T. L.; Silverman, R. B. Mechanistic Studies of Inactivation of Inducible Nitric Oxide Synthase by Amidines. Biochemistry 2015, 54, 2530-2538. Highlighted on the journal home page. PMCID: PMC4410366
341. Khanfar, M. A.; Quinti, L.; Wang, H.; Nobles, J.; Kazantsev, A. G.; Silverman, R. B. Design and evaluation of 3-(benzylthio)benzamide derivatives as potent and selective SIT2 inhibitors. ACS Med. Chem. Lett. 2015, 6, 607-611. PMCID: PMC4434462
342. Lee, H.; Le, H. V.; Wu, R.; Doud, E.; Sanishvili, R.; Kellie, J. F.; Compton, P. D.; Pachaiyappan, B.; Liu, D.; Kelleher, N. L.; Silverman, R. B. Mechanism of inactivation of GABA aminotransferase by (E)- and (Z)-(1S,3S)-3-amino-4-fluoromethylenyl-1-cyclopentanoic acid. ACS Chem. Biol. 2015, 2087-2098. PMCID: PMC4575653
343. Zigmond, E.; Ya’acov, A. B.; Lee, H.; Lichtenstein, Y.; Shalev, Z.; Smith, Y.; Zolotarov, L.; Ziv, E.; Kalman, R.; Le, H. V.; Lu, H.; Silverman, R. B.; Ilan, Y. Suppression of hepatocellular carcinoma by inhibition of overexpressed ornithine aminotransferase. ACS Med. Chem. Lett. 2015, 6, 840-844. PMCID: PMC4538432
344. Holden, J. K.; Kang, S.; Beasley, F. C.; Cinelli, M. A.; Li, H.; Roy, S. G.; Dejam, D.; Edinger, A. L.; Nizet, V.; Silverman, R. B.; Poulos, T. L. Nitric oxide synthase as a target for methicillin resistant Staphylococcus aureus. Chem. Biol. 2015, 22, 785-892. PMCID: PMC4475277
345. Teixeira-Castro, A.; Jalles, A.; Esteves, S.; Kang, S.; da Silva Santos, L.; Silva-Fernandes, A.; Neto, M.; Brielmann, R. M.; Bessa, C.; Duarte-Silva, S.; Miranda, A.; Oliveira, S.; Neves-Carvalho, A.; Bessa, J.; Summavielle, T.; Silverman, R. B.; Oliveira, P.; Morimoto, R. I.; Maciel, P. Serotonergic signaling suppresses ataxin-3 aggregation and neurotoxicity in animal models of Machado-Joseph disease. Brain, 2015, 138, 3221-3237.
346. Xie, C. B.; Shaikh, L. H.; Garg, S.; Tanriver, G.; Teo, A. E.; Zhou, J.; Maniero, C.; Zhao, W.; Kang, S.; Silverman, R. B.; Azizan, E. A. B.; Brown, M. J. Stimulation of aldosterone secretion by Cav1.3 mutation. Scientific Repts.In press.
347. Holden, J. K.; Dejam, D.; Lewis, M. C.; Huang, H.; Kang, S.; Jing, Q.; Xue, F.; Silverman, R. B.; Poulos, T. L. Inhibitor bound crystal structures of bacterial nitric oxide synthase. Biochemistry, 2015, 54, 4075-4082.
348. Kang, S.; Li, H.; Tang, W.; Martásek, P.; Roman, L. J.; Poulos, T. L.; Silverman, R. B. 2-Aminopyridines with a truncated side chain to improve human neuronal nitric oxide synthase inhibitory potency and selectivity. J. Med. Chem. 2015, 58, 5548-5560. PMCID: PMC4514563
349. Zhang, Y.; Zhao, K. T.; Fox, S. G.; Kim, J.; Kirsch, D. R.; Ferrante, R. J.; Morimoto, R. I.; Silverman, R. B. Tertiary amine pyrazolones and their salts as inhibitors of mutant superoxide dismutase 1-dependent protein aggregation for the treatment of amyotrophic lateral sclerosis. J. Med. Chem. 2015, 58, 5942-5949. PMCID: PMC4537347
350. Cinelli, M. A.; Li, H.; Pensa, A. V.; Kang, S.; Roman, L. J.; Martasek, P.; Poulos, T. L.; Silverman, R. B. Phenyl ether- and aniline-containing 2-aminoquinolines as potent and selective inhibitors of neuronal nitric oxide synthase. J. Med. Chem. 2015, 58, 8694-8712.PMCID: PMC4644118
351. Silverman, R. B. Basic science to blockbuster drug: invention of pregabalin (Lyrica®). Technol. Innov. 2016, 17, 153-158.
352. Wang, H.-Y.; Qin, Y.; Li, H.; Roman, L. J.; Martásek, P.; Poulos, T. L. Potent and selective human neuronal nitric oxide synthase inhibition by optimization of the 2-aminopyridine-based scaffold with a pyridine linker. J. Med. Chem. 2016, 59, 4913-4925. PMCID: PMC4882237
353. Li, H.; Wang, H.-Y.; Kang, S.; Silverman, R. B.; Poulos, T. L. Electrostatic control of isoform selective inhibitor binding in nitric oxide synthase. Biochemistry 2016, 55, 3702-3707.
354. Holden, J. K.; Lewis, M. C.; Cinelli, M. A.; Abdullatif, Z.; Pensa, A. V.; Silverman, R. B.; Poulos, T. L. Targeting Bacterial Nitric Oxide Synthase with Aminoquinoline-based Inhibitors. Biochemistry 2016, 55, 5587-5594.
355. Zheng, J.; Chen, L.; Schwake, M.; Silverman, R. B.; Krainc, D. Design and synthesis of potent qunazolines as selective b-glucocerebrosidase modulators. J. Med. Chem. 2016, 59, 8508-8520. PMCID: PMC5033727
356. Wu, R.; Sanishvili, R.; Belitsky, B. R.; Juncosa, J. I.; Le, H. V.; Lehrer, H. J. S.; Farley, M.; Silverman, R. B.; Petsko, G. A.; Ringe, D.; Liu, D. PLP and GABA trigger GabR-mediated transcription regulation in Bacillus subtilis via external aldimine formation. Proc. Natl. Acad. Sci. USA, 2017, 114, 3891-3896. PMCID: PMC5393194
357. Cinelli, M. A.; Li, H.; Chreifi, G.; Poulos, T. L.; Silverman, R. B. Nitrile In The Hole: Discovery of a Small Auxiliary Pocket in Neuronal Nitric Oxide Synthase Leading to the Development of Potent and Selective 2-Aminoquinoline Inhibitors. J. Med. Chem., 2017, 60(9), 3958-3978. PMICD: PMC5567828
358. Pensa, A.; Cinelli, M. A.; Li, H.; Chreifi, G.; Mukherjee, P.; Roman, L. J.; Martásek, P.; Poulos, T. L.; Silverman, R. B. Hydrophilic, Potent, and Selective 7-Substituted 2-Aminoquinolines as Improved Human Neuronal Nitric Oxide Synthase Inhibitors. J. Med. Chem. 2017, 60, 7146-7165. PMCID: PMC5570656
359. Mascarenhas, R.; Le, H. V.; Clevenger, K. D.; Lehrer, H. J., Ringe, D.; Kelleher, N. L.; Silverman, R. B.; Liu, D. Selective targeting by a mechanism-based inactivator against PLP-dependent enzymes: mechanisms of inactivation and alternative turnover. Biochemistry 2017,56, 4951-4961. PMCID: PMC 5624218
360. Do, H. T.; Wang, H.-Y.; Li, H.; Chreifi, G.; Poulos, T. L.; Silverman, R. B. Improvement of cell permeability of human neuronal nitric oxide synthase inhibitors using potent and selective 2-aminopyridine-based scaffolds with a fluorobenzene linker. J. Med. Chem. 2017, 60, 9360-9375.
361. Juncosa, J. I.; Takaya, K.; Le, H. V.; Moschitto, M. J.; Weerawarna, P. M.; Mascarenhas, R.; Liu, D.; Dewey, S. L.; Silverman, R. B. Design and mechanism of (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid, a highly potent GABA aminotransferase inactivator for the treatment of addiction. In revision.
362. Zheng, J.; Chen, L.; Skinner, O. S.; Remis, J.; Lansbury, P.; Skerlj, R.; Mrosek, M.; Heunisch, U.; Krapp, S.; Charrow, J.; Schwake, M.; Kelleher, N. L.; Silverman, R. B.; Krainc, D. b-Glucocerebrosidase modulators promote dimerization of b-glucocerebrosidase and reveal an allosteric binding site. Submitted
363. Khoury, T.; Rotnemer-Golinkin, D. D.; Zolotarev, L.; Juncosa, J. I.; Silverman, R. B.; Ilan, Y. Inactivation of Ornithine Aminotransferase Suppresses Primary Liver Cancer as a Result of Inhibition of Glutamine and Beta-Catenin and Suppression of Regulatory T Cells. Submitted
364. Silverman, R. B. Design and mechanism of GABA aminotransferase inactivators. Treatment of epilepsies and addictions. Chem. Rev. (invited). In preparation.
365. Zheng, J.; Chen, L.; Yu, X.; Kelleher, N. L.; Charrow, J.; Silverman, R. B.; Krainc, D. Activator-modified b-glucocerebrosidase for enzyme replacement therapy in Gaucher’s disease. In preparation.
363. Silverman, R. B. Design and mechanism of GABA aminotransferase inactivators, treatments for epilepsies and addictions. (invited) Chem. Rev. 2018, 118, 4037-4070.
364. Miley, G. P.; Rote, J. C.; Silverman, R. B.; Kelleher, N. L.; Thomson, R. J. Total synthesis of tambromycin enabled by indole C-H functionalization. Org. Lett. 2018, 20, 2369-2373. PMCID: PMC5953429
365. Moschitto, M. J.; Silverman, R. B. Synthesis of (S)-3-amino-4-(difluoromethylenyl)-cyclopent-1-ene-1-carboxylic acid (OV329), a potent inactivator of γ-aminobutyric acid aminotransferase. Org. Lett. 2018, 20, 4589-4592. PMCID: PMC6262895
366. Li, H.; Evenson, R. J.; Chreifi, G.; Silverman, R. B.; Poulos, T. P. The Structural Basis for Isoform Selective Nitric Oxide Synthase Inhibition by Thiophene-2-Carboximidamides. Biochemistry, 2018, 57, 6319-6325. PMCID: PMC6282162
367. Zheng, J.; Jeon, S.; Jiang, W.; Burbulla, L.; Oevel, K.; Krainc, D.; Silverman, R. B. Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase. J. Med. Chem. 2019, 62, 1218-1230. PMCID: PMC6467782
367a. Zheng, J.; Jeon, S.; Jiang, W.; Burbulla, L.; Oevel, K.; Krainc, D.; Silverman, R. B. Correction to Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase. J. Med. Chem. 2019, 62, 2850.
368. Burbulla, L. F.; Jeon, S.; Zheng, J.; Song, P.; Silverman, R. B.; Krainc, D. A modulator of wild- type glucocerebrosidase improves pathogenic phenotypes in dopaminergic neuronal models of Parkinson’s disease. Science Transl. Med., 2019, 11(514), eaau6870. PMCID: PMC7359409
- Do, H.T.; Li, H.; Chreifi, G.; Poulos, T. L.; Silverman, R. B. Optimization of blood brain barrier permeability with potent and selective human neuronal nitric oxide synthase inhibitors having a 2-aminopyridine scaffold. J. Med. Chem. 2019, 62, 2690-2707. PMCID: PMC6586428
- Moschitto, M. J.; Doubleday, P. F.; Catlin, D. S.; Kelleher, N. L.; Liu, D.; Silverman, R. B. Mechanism of inactivation of ornithine aminotransferase by (1S,3S)-3-amino-4-(hexafluoropropan-2-ylidenyl)cyclopentane-1-carboxylic acid. J. Am. Chem. Soc. 2019, 141, 10711-10721. PMCID: PMC6754100
- Cinelli, M. A.; Do, H. T.; Miley, G. P.; Silverman, R. B. Inducible nitric oxide synthase: regulation, structure, and inhibition. Med. Res. Rev. 2020, 40, 158-189. PMCID: PMC6908786
- Rey, S.; Maton, G.; Satake, S.; Llano, I.; Kang, S.; Surmeier, D. J.; Silverman, R. B.; Collin, T. Physiological involvement of presynaptic L-type voltage dependent calcium channels in GABA release of cerebellar molecular layer interneurons. J. Neurochem. 2020 in press.
- Cinelli, M. A.; Reidl, C. T.; Li, H.; Chreifi, G.; Poulos, T. L.; Silverman, R. B. First contact: 7-Phenyl-2-aminoquinolines, potent and selective neuronal nitric oxide synthase inhibitors that target an isoform-specific aspartate. J. Med. Chem. 2020, 63 (9), 4528–4554. PMCID: PMC7429991
- Catlin, D. S.; Reidl, C. T.; Trzupek, T. R.; Silverman, R. B.; Cannon, B.; Becker, D. P.; Liu, D. (S)-4-Amino-5-phenoxypentanoate designed as a potential selective agonist of the bacterial transcription factor GabR. Protein Sci. 2020, 29, 1816-1828. 10.1002/pro.3905.
- Shen, S.; Doubleday, P. F.; Weerawarna, P. M.; Zhu, W.; Kelleher, N. L.; Silverman, R. B. Mechanism-based design of 3-amino-4-halocyclopentenecarboxylic acids as inactivators of g-aminobutyric acid aminotransferase. ACS Med. Chem. Lett. 2020, in press.
- Zhu, W.; Doubleday, P. F.; Catlin, D. S.; Weerawarna, P. M.; Butrin, A.; Shen, S.; Wawrzak, Z.; Kelleher, N. L.; Liu, D.; Silverman, R. B. A remarkable difference that one fluorine atom confers on the mechanisms of inactivation of human ornithine aminotransferase by two cyclohexene analogues of g-aminobutyric acid. J. Am. Chem. Soc. 2020, 142, 4892-4903. PMCID: PMC7134380
- Silverman, R. B. Drug discovery: ingenuity and serendipity…or is it the other way around? Med. Chem. Rev. 2020, 55, Chapter 1, in press. http://dx.doi.org/10.29200/acsmedchemrev-v55.ch1
- Cooper, G.; Kang, S.; Perez-Rosello, T.; Guzman, J. N.; Galtieri, D.; Xie, Z.; Kondapalli, J.; Mordell, J.; Silverman, R. B.; Surmeier, D. J. A single amino acid determines the selectivity and efficacy of selective negative allosteric modulators of CaV1.3 L-type calcium channels.ACS Chem. Biol. 2020, 15, 2539-2550. PMCID: PMC7502546
- Butrin, A.; Beaupre, B.; Kadamandla, N.; Zhao, P.; Shen, S.; Silverman, R. B.; Moran, G. R.; Liu, D. Structural and kinetic analyses reveal the dual inhibition modes of human ornithine aminotransferase by (1S,S)-3-amino-4-(hexafluoropropan-2-ylidenyl)-cyclopentane-1-carboxylic acid (BisCF3).
ACS Chem. Biol. 2021,16, 67-75. PMCID: PMC8474141
-
Genç, B.; Gautam, M.; Gözütok, Ö.; Dervishi, I.; Sanchez, S.; Goshu, G. M.; Koçak, N.; Xie, E.; Silverman, R. B.; Özdinler, P. H. Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP-43 pathology. Clin. Transl. Med., 2021, 11, e336. PMCID: PMC789803
- Weerawarna, P. M.; Moschitto, M. J.; Silverman, R. B. Theoretical and mechanistic studies of the inactivation of GABA aminotransferase by OV329 and CPP-115. Determination of the rate-limiting step and validation of the global kinetic parameters. ACS Chem. Biol., 2021, 16, 615-630. PMCID: PMC837171
- Sadleir, K. R.; Popovoic, J.; Zhu, W.; Reidel, C. T.; Do, H.; Silverman, R. B.; Vassar, R. Pregabalin treatment does not affect amyloid pathology in 5XFAD mice. Curr. Alzheimer Res. 2021, 18, 283-297.https://doi.org/10.2174/1567205018666210713125333
- Shen, S.; Butrin, A.; Doubleday, P. F.; Melani, R. D.; Beaupre, B. A.; Tavares, M. T.; Ferreira, G. M.; Kelleher, N. L.; Moran, G. R.; Liu, D.; Silverman, R. B. Turnover and inactivation mechanisms for (S)-3-amino-4,4-difluorocyclopent-1-enecarboxylic acid, a selective mechanism-based inactivator of human ornithine aminotransferase. J. Am. Chem. Soc. 2021, 143, 8689-8703. PMCID: PMC836702
- Zhu, W.; Doubleday, P. F.; Butrin, A.; Weerawarna, P. M.; Melani, R.; Catlin, D. S.; Dwight, T. A.; Liu, D.; Kelleher, N. L.; Silverman, R. B. Remarkable and unexpected mechanism for (S)-3-amino-4-(difluoromethylenyl)cyclohex-1-ene-carboxylic acid as a selective inactivator of human ornithine aminotransferase. J. Am. Chem. Soc. 2021, 143, 8193-8207. PMCID: PMC836938
- Feja, M.; Meller, S.; Deking, L. S.; Kaczmarek, E.; During, M. J.; Silverman, R. B.; Gernert, M. OV329, a novel highly potent GABA aminotransferase inactivator, induces pronounced anticonvulsant effects in the pentylenetetrazole seizure threshold test and in amygdala-kindled rats. Epilepsia 2021, 00, 1-14.
- Silverman, R. B. Inactivators of ornithine aminotransferase for the treatment of hepatocellular carcinoma. ACS Med. Chem. Lett. 2022, 13, 38-49. PMCID: PMC8762738
- Tong, S.; Cinelli, M.; Ibrahim, N.; Huang, H.; Silverman, R. B.; Yang, S. Inhibition of interferon-gamma-stimulated melanoma progression by targeting neuronal nitric oxide synthase (nNOS). Scientific Reports, 2022, 12, 1701. PMCID: PMC8807785